

**Survival CURRICULUM VITAE  
OREGON HEALTH & SCIENCE UNIVERSITY**

**NAME** Rita M. Braziel

**DATE** 04/15/2014

**PRESENT POSITION AND ADDRESS**

**Academic Rank:** Professor  
**Department / Division:** Pathology  
**Professional Address:** Oregon Health and Sciences University  
Dillehunt Hall, Room 6040  
Mail Code: L471  
3181 SW Sam Jackson Park Road  
Portland, OR 97201-3098  
Office: (503)-494-2315  
Fax: (503)-494-8148  
**E-Mail Address:** [braziel@ohsu.edu](mailto:braziel@ohsu.edu)

**I. BIOLOGICAL**

**Birthdate\*:**

**Marital Status/  
Children\*:**

**Home Address\*:**

**Social Security  
No.\*:**

*\*Optional*

**II. EDUCATION**

**Undergraduate and Graduate (Include Year, Degree, and Institution):**

B.S. in Biology and B.S. in Chemistry, Univ. of New Mexico,  
Albuquerque, New Mexico. Graduated magna cum laude, and with  
honors in Biology  
M.D., Univ. of New Mexico Medical School, Albuquerque, New  
Mexico.

**Postgraduate (Include Year, Degree, and Institution):**

Pathology Fellowship, Univ. of New Mexico. Preceptor - (b)(6),  
M.D., Chairman of Pathology  
Pathology Residency, UNM Affiliated Hospitals, Albuquerque, New Mexico -  
Combined Anatomic and Clinical Pathology  
Medical Staff Fellow in Hematopathology, Laboratory of Pathology, National  
Cancer Institute, National Institutes of Health, Bethesda, Maryland. Chief of  
Program: (b)(6), M.D.

(b)(6)  
(b)(6)  
(b)(6)

**Certification (Include Board, Number, Date, and Recertification):**

Diplomate--National Board of Medical Examiners (1977)  
American Board of Pathology, Anatomic & Clinical Pathology (1981)

**Licenses (Include State, Date, Status, Number, and Renewal Date):**

New Mexico (1979, 79-132 - inactive)  
Oregon (1984, 13970 - active)

**III. PROFESSIONAL EXPERIENCE**

**Academic (Include Year, Position, and Institution):**

- Professor, Department of Pathology, Oregon Health and Science University 2005-present
- Associate Professor, Department of Pathology, Oregon Health and Science University 0.3 FTE from 1994-2001  
0.8 FTE from 2001-2004  
1.0 FTE after 3/2004
- Assistant Professor, Department of Pathology, Oregon Health and Science University 1.0 FTE from 1984-1994
- Director of Legacy Hematopathology Services and Hoffman Cellular and Molecular Diagnostics Laboratory 0.7 FTE from 7/1994-4/2001  
0.2 FTE from 4/2001-3/2004
- Hematopathology Consultant for Legacy Laboratories 0.05 FTE from 4/2004-present

**Administrative (Include Year, Position, and Institution):**

- Director - OHSU Hematopathology Division 1984-1994, 1998-present
- Director of OHSU Hematopathology Molecular Diagnostics 1986-1994
- Director of OHSU Hematopathology Flow Cytometry 1985-2001
- Director of Legacy Hematopathology Services and Hoffman Cellular and Molecular Diagnostics Laboratory 0.7 FTE from 7/1994-4/2001  
0.2 FTE from 4/2001-3/2004

**IV. SCHOLARSHIP**

**Grants and Contracts:**

Other Support (Include Title, Source, PI, Amount Period, and % Effort)

- Co-Investigator and OHSU PI – Lymphoma/Leukemia Molecular Profiling Project (LLMPP) NIH Consortium Grant (Molecular Signatures to Improve Diagnosis and Outcome Prediction in Non-Hodgkin Lymphoma). OHSU budget component of \$25,000 per year for five years (2011-2016), with (b)(6) indirects.
- Co-Investigator and OHSU PI – Lymphoma/Leukemia Molecular Profiling Project (LLMPP) NIH Consortium Grant. OHSU budget component of \$35,000 per year for five years (2005-2010), with (b)(6) indirects.
- Co-Chair - *SWOG Lymphoma Translation Medicine Committee 2004-2009*. Competitive renewal grant budget includes a small salary support component.
- National Coordinator for SWOG 0016 – *A Phase III Trial of CHOP vs CHOP + Rituximab vs CHOP + Iodine-131-Labeled Monoclonal Anti-B1 Antibody (Tositumomab) for Treatment of Newly Diagnosed*

*Follicular Non-Hodgkin's Lymphomas*. Clinical trial opened April, 2001. Sponsored clinical trial research – Glaxo-Smith-Kline funding for biologic studies (b) (4), with (b) (4) indirects – 2006-2011).

- Principal Investigator – Project #6979 – Initial IRB approval 3/14/2002. *Gene Expression Monitoring by Gene Chip Microarray in Patients with Lymphoma and Leukemia*. Funding for first year from Gene Logic of (b) (4) (b) (4) indirects (b) (4).
- National Coordinator and Principal Investigator for Biologic Studies - *SWOG 9911 Phase II Pilot Trial of CHOP Followed by Iodine-131-Labeled Monoclonal Anti-CD20 Antibody For Treatment of Newly Diagnosed Follicular Non-Hodgkin's Lymphomas*. Sponsored clinical trial research - (b) (4) grant from Coulter for biologic studies (b) (4) indirects), 2000-2003.
- Principal Investigator – Project # 0471-753 – IRB approval 3/14/2002. *Analysis of Proto-Oncogene Activation and Abnormalities of Signal Transduction Pathways for Identification of Potential Prognostic Markers and Therapeutic Targets in Follicular Lymphoma*. SWOG Developmental Research award of (b) (4) (no indirects), January 1-December 31, 2002.
- National Coordinator and Principal Investigator for Biologic Studies - *SWOG 9800 Phase II Pilot Trial of CHOP Followed by Monoclonal Antibody Anti-CD20 for Treatment of Newly Diagnosed Follicular Non-Hodgkin's Lymphomas*. Sponsored clinical trial research - (b) (4) grant from Genentech for biologic studies (b) (4) indirects), 1999-2002.
- Principal Investigator - *Central Pathology Review of Phase II Open-Label Study to Determine the Safety and Anti-Leukemic Effects of STI571 in Patients with Philadelphia Chromosome-Positive Chronic Myeloid Leukemia in Myeloid Blast Crisis*. Grant from Novartis of (b) (4) (b) (4) indirects (b) (4), 7/15/2000-11/30/2000.
- Tartar Trust, (b) (4), 1992.
- Medical Research Foundation Grant, (b) (4), 1986-87
- Tartar Trust, (b) (4) 1986

#### **Publications/Creative Work:**

Peer-reviewed:

1. Jones AM, Mann J, and Braziel RM: Human Plague in New Mexico: Report of three autopsied cases. *J. Forensic Sci.* 24:1, 1979.
2. Van Epps DE, Braziel R, Tung K, and Warner N: Identification by flow cytometry of human monocytes with fucose-binding lectin (FBL) from lotus tetragonolobus seeds. *J. RES.* 34:113-123, 1983.
3. Braziel RM, Keneklis T, Donlon JA, Hsu SM, Cossman J, Bollum FJ, and Jaffe ES: Terminal deoxynucleotidyl transferase in non-Hodgkin's lymphoma. *Am J Clin Pathol.* 80:655-659, 1983.
4. Cossman J, Neckers LM, Braziel RM, Trepel JB, Korsmeyer SJ, and Bakhshi A: In vitro enhancement of immunoglobulin gene expression in chronic lymphocytic leukemia. *J Clin Invest.* 73:587-592, 1984.
5. Donohue JH, Lotze MT, Robb RJ, Rosenstein M, Braziel RM, Jaffe ES, and Rosenberg SA: In vivo administration of purified Jurkat-derived interleukin 2 in mice. *Cancer Res.* 44:1380-1386, 1984
6. Braziel RM, Sussman E, Neckers LM, Jaffe ES and Cossman J: Induction of immunoglobulin secretion in follicular non-Hodgkin's lymphomas: Role of immunoregulatory T cells. *Blood* 66:128-134, 1985.
7. Matory YL, Chang AE, Lipford EH III, Braziel R, Hyatt CL, McDonald HD, and Rosenberg SA: Toxicity of recombinant human interleukin-2 in rats following intravenous infusion. *J Biol Response Mod* 4:377-390, 1985.
8. Neuwelt EA, Frenkel EP, Gummerlock MK, Braziel RM, Dana B, and Hill SA: Developments in the diagnosis and treatment of primary CNS lymphoma. *Cancer* 58:1609-1620, 1986.
9. Braziel RM: A marker for monoclonality of T-cell malignancy. *Western J. of Med.* 145:377, 1986.
10. Bakke AC, Sahin A, and Braziel RM: Applications of flow cytometry in surgical pathology. *Lab Med* 18:590-596, 1986.

11. Matory YL, Chang AE, Lipford EH III, Braziel R, Hyatt CL, and Rosenberg SA: The toxicity of recombinant human interleukin-2 in rats following intravenous infusion. *J Natl Med Assoc* 79:537-541, 1987.
12. Traweek ST, Riscoe MK, Ferro AJ, Braziel RM, Magenis RE, and Fitchen JA: Methylthioadenosine phosphorylase deficiency in acute leukemia: pathologic, cytogenetic, and clinical features. *Blood*. 71:1568-1573, 1988.
13. Phillips DL, Keeffe EB, Benner KG, and Braziel RM: Colonic lymphoma in the transplant patient. *Dig Dis Sci*. 34:150-154, 1989.
14. Traweek ST, Ben-Ezra J, Braziel RM, and Winberg CD: The in-vitro response of CD2-positive acute myelogenous leukemia to proliferation and differentiation inducing agents. *Leuk Res*. 14:433-440, 1990.
15. Lee RG, Braziel RM, and Stenzel P: Gastrointestinal involvement in Langerhans cell histiocytosis (histiocytosis X): diagnosis by rectal biopsy. *Mod Pathol*. 3:154-157, 1990.
16. Ridgeway D, Benda GI, Magenis E, Allen A, Segal GM, Braziel RM, and Neerhout RC: Transient myeloproliferative disorder of the Downs type in the normal newborn. *Amer J Dis Child* 144:1117-1119, 1990.
17. Gonzalez CL, Medeiros LJ, Braziel RM, and Jaffe ES: T-cell lymphoma involving subcutaneous tissue: A clinicopathologic entity commonly associated with hemophagocytic syndrome. *Amer J Surg Pathol*. 15:17-27, 1991.
18. Neuwelt EA, Goldman DL, Dahlborg SA, Crossen J, Ramsey R, Roman-Goldstein S, Braziel RM, and Dana B: Primary central nervous system lymphoma treated with osmotic blood-brain barrier disruption: Prolonged survival and preservation of cognitive function. *J Clin Oncol* 9:1580-1590, 1991.
19. Specht HD, Bakke AC, Braziel RM, Miley A, Rashidi-Nezami S, and Germain L: Cellular basis for the elevated Gallium-67 computed lung index in rheumatoid lung patient. *J Nucl Med* 32:2288-2290, 1991.
20. Sanguenza OP, Yadav S, White CR, and Braziel RM: Evolution of B-cell lymphoma from pseudolymphoma: A multidisciplinary approach utilizing histology, immunohistochemistry and Southern blot analysis. *Am J Dermatopathol*. 14:408-413, 1992.
21. Wilson DJ, Braziel RM, Rosenbaum JT: Intraocular lymphoma: Immunopathologic analysis of vitreous biopsies. *Arch Ophthalmol* 110:1455-1458, 1992.
22. Hammer E, Sanguenza O, Suwanjindar P, White CR, Braziel RM: Immunophenotypic and genotypic analysis in cutaneous lymphoid hyperplasia. *J Amer Acad Dermatol*. 28:426-33, 1993.
23. Braziel RM, Sacker AR. Gene rearrangements in malignant lymphomas. *Cancer Treat Res*. 66:147-65, 1993.
24. Davidson M, Braziel RM, Lairmore MD, Jacobson S, Sprott JM, Tucker SB, Levine PH, Kaplan JE: Atypical human T-cell lymphotropic virus type-I-associated T-cell lymphoma in a low-prevalence Alaska Native population: Implications for disease surveillance. *Cancer* 71:4072-4076, 1993.
25. Trumper LH, Brady G, Bagg A, Loke SL, Gray D, Wagman R, Braziel R, Vicini S, Iscove NN, Cossman J, Mak TW: Single-cell analysis of Reed-Sternberg cells: Heterogeneity of gene expression in morphologically and phenotypically similar Hodgkin's disease. *Blood* 81:3097-3115, 1993.
26. Miller TP, Grogan TM, Dahlberg S, Spier CM, Braziel RM, Banks PM, Foucar K, Kjeldsberg CR, Levy N, Nathwani BN, Schnitzer R, Tubbs R, Gaynor ER, Fisher RI: Prognostic significance of the Ki-67-associated proliferative antigen in aggressive non-Hodgkin's lymphomas: A prospective Southwest Oncology (SWOG) trial. *Blood* 83:1460-1466, 1994.
27. Traweek ST, Liu J, Braziel RM, Johnson RM, Brynes RK: Detection of myeloperoxidase gene expression in minimally differentiated acute myelogenous leukemias (AML-M0) using in situ hybridization. *Diagn Mol Pathol* 4: 212-219, 1995.
28. Head DR, Kopecky K, Weick J, Files J, Ryan D, Foucar K, Montiel M, Bickers J, Fishleder A, Miller M, Spier C, Hanson C, Bitter M, Braziel R, Mills G, Welborn J, Williams W, Hewlett J, Willman C, Appelbaum F: Effect of aggressive daunomycin therapy on survival in acute promyelocytic leukemia. *Blood* 86: 1717-1728, 1995.

29. Mongeon CA, Foucar K, and Braziel RM: Hematopathology ASCP Check Sample - ASCP ChecksampleNo. HP 95-4 (Systemic Polyclonal Immunoblastic Proliferations.) Hematopathology Volume 1, No. 4, 1995.
30. Dahlborg SA, Henner WD, Crossen JR, Tableman M, Petrillo A, Braziel RM, and Neuwelt EA: Non-AIDS primary CNS lymphoma: The first example of a durable response in a primary brain tumor using enhanced chemotherapy delivery without cognitive loss and without radiotherapy. *Cancer J Sci Am* 2: 166-174, 1996.
31. Braziel RM: A multi-institutional perspective: The Southwest Oncology Group Lymphoma Biology Laboratory Experience with Prognostic Markers. *Am J Surg Pathol* 20: 371-379, 1996.
32. Sanguenza OP, Galloway J, Gulley ML, Eagan PA, and Braziel RM: Absence of Epstein-Barr virus in lymphomatoid papulosis: An immunohistochemical and in situ hybridization study. *Arch Dermatol* 132: 279-282, 1996.
33. Braziel RM, Galloway JR: Laboratory Investigations in the diagnosis of primary central nervous system lymphomas. *Pathology Case Reviews*. September/October, 1996.
34. Braziel RM, Oyama K: Mistaken Diagnoses of Hodgkin's Disease. *Hematol Oncol Clin North Am*. 11:863-892, 1997.
35. Gross ND, Wilson DJ, Dailey RA, Beckstead JH, and Braziel RM: Nodular sclerosing Hodgkin's disease with primary manifestation in orbit. *Ophthal Plast and Reconstr Surg*. 14:169-173, 1998.
36. Messineo C, Jamerson MH, Hunter E, Braziel R, Bagg A, Irving SG, and Cossman J: Gene expression by single Reed-Sternberg cells: Pathways of apoptosis and activation. *Blood* 91:2443-2451, 1998.
37. Braziel RM, Arber DA, Slovak ML, Gulley ML, Spier C, Kjeldsberg C, Unger J, Miller TP, Fisher RI, Tubbs R, Leith C, and Grogan TM: The Burkitt-like lymphomas: A Southwest Oncology Group study delineating phenotypic, genotypic and clinical features. *Blood* 97:3713-3720, 2001.
38. Arber DA, Braziel RM, Bagg A, and Bijwaard KE: Evaluation of T-cell receptor testing in lymphoid neoplasms: Results of a multicenter study of 29 extracted DNA and paraffin-embedded samples. *J Mol Diagn* 3:133-140, 2001.
39. Bagg A, Braziel RM, Arber DA, Bijwaard KE, and Chu AY: Immunoglobulin heavy chain gene analysis in lymphomas: a multicenter study demonstrating the heterogeneity of performance of polymerase chain reaction assays. *J Mol Diagn* 4:81-89, 2002.
40. Hsi E, Tubbs RR, Lovell MA, Braziel RM, and Gulley ML: Detection of bcl-2/J(H) translocation by polymerase chain reaction: a summary of the experience of the Molecular Oncology Survey of the College of American Pathologists. *Arch Pathol Lab Med* 126:902-908, 2002.
41. Braziel RM, Launder TM, Druker BJ, Olson SB, Magenis RE, Mauro MJ, Sawyers CL, Paquette RL, and O'Dwyer ME: Hematopathologic and cytogenetic findings in imatinib mesylate-treated chronic myelogenous leukemia patients: 14 months experience. *Blood* 100:435-441, 2002.
42. Gatter KM, Rader A, and Braziel RM: Fine-needle aspiration biopsy of anaplastic large cell lymphoma, small cell variant with prominent plasmacytoid features: case report. *Diag Cytopathol* 26:113-116, 2002.
43. Fan G, Kotylo P, Neiman RS, and Braziel RM: Comparison of fascin expression in anaplastic large cell lymphoma and classical Hodgkin disease. *Am J Clin Pathol* 119:199-204, 2003.
44. Smith JR, Braziel RM, Paoletti S, Lipp M, Uguccioni M, and Rosenbaum JT: Expression of B-cell-attracting chemokine 1 (CXCL13) by malignant lymphocytes and vascular endothelium in primary central nervous system lymphoma. *Blood* 101:815-821, 2003.
45. O'Dwyer ME, Gatter KM, Loriaux M, Druker BJ, Olson SB, Magenis RE, Lawce H, Mauro MJ, Maziarz RT, and Braziel RM: SPOTLIGHT: Demonstration of Philadelphia chromosome negative abnormal clones in patients with chronic myelogenous leukemia during major cytogenetic responses induced by imatinib mesylate. *Leukemia* 17:481-487, 2003.

46. Press OW, Unger JM, Brazier RM, Maloney DG, Miller TP, LeBlanc M, Gaynor ER, Rivkin SE, and Fisher RI: A phase 2 trial of CHOP chemotherapy followed by tositumomab/Iodine I131 tositumomab for previously untreated follicular non-Hodgkin lymphoma: Southwest Oncology Group Protocol S9911. *Blood* 102;1606-1612, 2003.
47. Brazier RM, Shipp MA, Feldman AL, Espina V, Winters M, Jaffe ES, Petricoin EF 3<sup>rd</sup>, Liotta LA. Molecular diagnostics. *Hematology (Am Soc Hematol Educ Program)*. 279-93, 2003.
48. Rosenwald A, Wright G, Leroy K, Yu X, Gaulard P, Gascoyne RD, Chan WC, Zhao T, Haioun C, Greiner TC, Weisenburger DD, Lynch JC, Vose J, Armitage JO, Smeland EB, Kvaloy S, Holte H, Delabie J, Campo E, Montserrat E, Lopez-Guillermo A, Ott G, Muller-Hermelink HK, Connors JM, Brazier R, Grogan TM, Fisher RI, Miller TP, LeBlanc M, Chiorazzi M, Zhao H, Yang L, Powell J, Wilson WH, Jaffe ES, Simon R, Klausner RD, and Staudt LM for the Leukemia and Lymphoma Molecular Profiling Project. Molecular diagnosis of primary mediastinal B cell lymphoma identifies a clinically favorable subgroup of diffuse large B cell lymphoma related to Hodgkin lymphoma. *J Exp Med* 198;851-862, 2003.
49. Hans CP, Weisenburger DD, Greiner TC, Gascoyne RD, Delabie J, Ott G, Muller-Hermelink HK, Campo E, Brazier RM, Jaffe ES, Pan Z, Farinha P, Smith LM, Falini B, Banham AH, Rosenwald A, Staudt LM, Connors JM, Armitage JO, Chan WC: Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. *Blood* 103;275-282, 2004.
50. Rimsza L, Roberts RA, Miller TP, Unger JM, LeBlanc M, Brazier RM, Weisenberger DD, Chan WC, Muller-Hermelink HK, Jaffe ES, Gascoyne RD, Campo E, Fuchs DA, Spier CM, Fisher RI, Delabie J, Rosenwald A, Staudt LM, Grogan TM. Loss of MHC class II gene and protein expression in diffuse large B-cell lymphoma is related to decreased tumor immunosurveillance and poor patient survival regardless of other prognostic factors: a follow-up study from the Leukemia and Lymphoma Molecular Profiling Project. *Blood* 103;4251-4258, 2004.
51. Kussick SJ, Kalnoski M, Brazier RM, Wood BL. Prominent clonal B-cell populations identified by flow cytometry in histologically reactive lymphoid proliferations. *Amer J Clin Pathol* 121;464-472, 2004.
52. Griswold IJ, Shen LJ, LaRosee P, Demehri S, Heinrich MC, Brazier RM, McGreevey L, Haley AD, Giese N, Druker BJ, Deininger MW. Effects of MLN518, a dual FLT3 and KIT inhibitor, on normal and malignant hematopoiesis. *Blood* 104;2912-2918, 2004.
53. Iqbal J, Sanger WG, Horsman DE, Rosenwald A, Pickering DL, Dave S, Xiao L, Cao K, Zhu Q, Sherman S, Hans CP, Weisenburger DD, Greiner TC, Gascoyne RD, Ott G, Muller-Hermelink HK, Delabie J, Brazier RM, Jaffe ES, Campo E, Lynch JC, Connors JM, Vose JM, Armitage JO, Grogan TG, Staudt LM, Chan WC for the Leukemia/ Lymphoma Molecular Profiling Project (LLMPP). BCL2 translocation defines a unique tumor subset within the germinal center B-cell-like diffuse large B-cell lymphomas. *Am J Pathol* 165;159-166, 2004.
54. Dave SS, Wright G, Tan B, Rosenwald A, Gascoyne RD, Chan WC, Fisher RI, Brazier RM, Rimsza LM, Grogan TM, Miller TP, LeBlanc M, Greiner TC, Weisenburger DD, Lynch JC, Vose J, Armitage JO, Smeland EB, Kvaloy S, Holte H, Delabie J, Connors JM, Lansdorp PM, Ouyang Q, Lister TA, Davies AJ, Norton AJ, Muller-Hermelink HK, Ott G, Campo E, Montserrat E, Wilson WH, Jaffe ES, Simon R, Yang L, Powell J, Zhao H, Goldschmidt N, Chiorazzi M, Staudt LM for the Lymphoma/Leukemia Molecular Profiling Project. Prediction of survival in follicular lymphoma based on molecular features of tumor-infiltrating immune cells. *N Engl J Med* 351;2159-2169, 2004.
55. Huang J, Fan G, Zhong Y, Gatter K, Brazier R, Gross G, Bakke A: Diagnostic usefulness of aberrant CD22 expression in differentiating neoplastic cells of B-cell chronic lymphoproliferative disorders from admixed benign B cells in four-color multiparameter flow cytometry. *Am J Clin Pathol* 123:826-832, 2005.
56. Fu K, Weisenburger DD, Greiner TC, Chiorazzi M, Dave S, Wright G, Rosenwald A, Chiorazzi M, Iqbal J, Gesk S, Siebert R, De Jong D, Jaffe ES, Wilson WH, Delabie J, Ott G, Dave BJ, Sanger WG, Smith LM, Rimsza L, Brazier RM, Muller-Hermelink HK, Campo E, Gascoyne RD, Staudt LM, Chan WC for the Lymphoma/Leukemia Molecular Profiling Project. Cyclin D1-negative mantle cell lymphoma: A clinicopathologic study based on gene expression profiling. *Blood* 106;4315-4321, 2005.
57. Zu Y, Steinberg SM, Campo E, Hans CP, Weisenburger DD, Brazier RM, Delabie J, Gascoyne RD, Muller-Hermelink, Pittaluga S, Raffeld M, Chan WC, Jaffe ES for the Pathology Panel of the Lymphoma/Leukemia Molecular Profiling Project: Validation of tissue microarray immunohistochemistry staining and interpretation in

diffuse large B-cell lymphoma. *Leuk Lymphoma* 46;693-701, 2005.

58. Coupland SE, Loddenkemper C, Smith JR, Braziel RM, Anagnostopoulous I CF, Stein H. Expression of immunoglobulin transcription factors in primary intraocular lymphoma and primary central nervous system lymphoma. *Invest Ophthalmol Vis Sci* 46;3957-3964, 2005.
59. Falkenhagen KM, Braziel RM, Fraunfelder RW, Smith JR. B-cells in ocular adnexal lymphoproliferative lesions express B-cell attracting chemokine 1 (CXCL13). *Am Journal Ophthal* 140;335-337, 2005.
60. Fan G, Molstad M, Braziel RM, Standley M, Huang J, Rodgers W, Nagalla S: Proteomic profiling of mature CD10+ B-cell lymphomas. *Am J Clin Pathol.*124;920-929, 2005.
61. Bea S, Zettl A, Wright G, Salaverria I, Jehn P, Moreno V, Burek C, Ott G, Puig X, Yang L, Lopez-Guillermo, Chan WC, Greiner TC, Weisenburger DD, Armitage JO, Gascoyne RD, Connors JM, Grogan TM, Braziel R, Fisher RI, Smeland EB, Kvaloy S, Holte H, Delabie J, Simon R, Powell J, Wilson WH, Jaffe ES, Montserrat E, Muller-Hermelink HK, Staudt LM, Campo E, Rosenwald A, for the Lymphoma/Leukemia Molecular Profiling Project. Diffuse large B-cell lymphoma subgroups have distinct genetic profiles that influence tumor biology and improve gene-expression-based survival prediction. *Blood* 106;3183-3190, 2005.
62. Rimsza LM, Roberts RA, Campo E, Grogan TM, Salaverria I, Zettl A, Rosenwald A, Ott G, Muller-Hermelink HK, Delabie J, Fisher RI, Unger JM, Leblanc M, Staudt LM, Jaffe ES, Gascoyne RD, Chan WC, Weisenburger DD, Greiner T, Braziel RM, Miller TP. Loss of major histocompatibility class II expression in non-immune-privileged site diffuse large B-cell lymphoma is highly coordinated and not due to chromosomal deletions. *Blood* 107;1101-7, 2006.
63. Greiner TC, Dasgupta C, Ho VV, Weisenburger DD, Smith LM, Lynch JC, Vose JM, Fu K, Armitage JO, Braziel RM, Campo E, Delabie J, Gascoyne RD, Jaffe ES, Muller-Hermelink HK, Ott G, Rosenwald A, Staudt LM, Im MY, Karaman MW, Pike BL, Chan WC, Hacia JG. Mutation and genomic deletion status of ataxia telangiectasia mutated (ATM) and p53 confer specific gene expression profiles in mantle cell lymphoma. *Proc Natl Acad Sci USA* 103; 2352-7, 2006.
64. Dave SS, Fu K, Wright GW, Lam LT, Kluin P, Boerma EJ, Greiner TC, Weisenburger DD, Rosenwald A, Ott G, Muller-Hermelink HK, Gascoyne RD, Delabie J, Rimsza LM, Braziel RM, Grogan TM, Campo E, Jaffe ES, Dave BJ, Sanger W, Bast M, Vose JM, Armitage JO, Connors JM, Smeland EB, Kvaloy S, Holte H, Fisher RI, Miller TP, Montserrat E, Wilson WH, Bahl M, Zhao H, Yang L, Powell J, Simon R, Chan WC, Staudt LM; Lymphoma/Leukemia Molecular Profiling Project. Molecular diagnosis of Burkitt's lymphoma. *N Engl J Med* 354; 2431-42, 2006.
65. Press OW, Unger JM, Braziel RM, Maloney DG, Miller TP, Leblanc M, Fisher RI: Southwest Oncology Group. Phase II trial of CHOP chemotherapy followed by Tositumomab/Iodine I-131 Tositumomab for previously untreated follicular non-Hodgkin's lymphoma: five year follow-up of Southwest Oncology Group Protocol S9911. *J Clin Oncol* 24;4143-9, 2006.
66. Schittenhelm MM, Yee KW, Tyner JW, McGreevey L, Haley AD, Town A, Griffith DJ, Bainbridge T, Braziel RM, O'Farrell AM, Cherrington JM, Heinrich MC. FLT3 K663Q is a novel AML-associated oncogenic kinase: Determination of biochemical properties and sensitivity to Sunitinib (SU11248). *Leukemia* 20;2008-14, 2006.
67. Zhong Y, Bakke AC, Fan G, Braziel RM, Gatter KM, Leis JF, Maziarz RT, Huang JZ. Drug resistance in B-cell chronic lymphocytic leukemia: predictable by in vitro evaluation with a multiparameter flow cytometric cytotoxicity assay. *Cytometry B Clin Cytom.* 72;189-95, 2007.
68. Smith JR, Lanier VB, Braziel RM, Falkenhagen KM, White C, Rosenbaum JT. Expression of vascular endothelial growth factor and its receptors in rosacea. *Br J Ophthalmol* 91;226-9, 2007.
69. Davies AJ, Rosenwald A, Wright G, Lee A, Last KW, Weisenburger DD, Chan WC, Delabie J, Braziel RM, Campo E, Gascoyne RD, Jaffe ES, Muller-Hermelink K, Ott G, Calaminici M, Norton AJ, Goff LK, Fitzgibbon J, Staudt LM, Lister AT. Transformation of follicular lymphoma to diffuse large B-cell lymphoma proceeds by distinct oncogenic mechanisms. *Br J Haematol.* 136;286-93, 2007.
70. Smith JR, Falkenhagen KM, Coupland SE, Chipps TJ, Rosenbaum JT, and Braziel RM: Malignant B cells from

patients with primary central nervous system lymphoma express Stromal Cell-Derived Factor-1 (SDF-1/ CXCL12). *Amer J Clin Pathol* 127;633-41, 2007.

71. Nikiforova MN, His ED, Braziel RM, Gulley ML, Leonard DG, Nowak JA, Tubbs RR, Vance GH, Van Deerlin VM; Molecular Pathology Resource Committee, CAP. Detection of clonal IGH gene rearrangements: summary of Molecular Oncology Surveys of the College of American Pathologists. *Arch Pathol Lab Med* 131;185-9, 2007.
72. Gulley ML, Braziel RM, Halling KC, His ED, Dant JA, Nikiforova MN, Nowak JA, Ogino S, Oliveira A, Polesky HF, Silverman L, Tubbs RR, Van Deerlin VM, Vance GH, Versalovic J; Molecular Pathology Resource Committee, CAP. Clinical laboratory reports in molecular pathology. *Arch Pathol Lab Med*. 131;852-63, 2007.
73. Rimsza LM, Leblanc ML, Unger JM, Miller TP, Grogan TM, Persky DO, Martel RR, Sabalos CM, Seligmann B, Braziel RM, Campo E, Rosenwald A, Connors JM, Sehn LH, Johnson N, Gascoyne RD. Gene expression predicts overall survival in paraffin embedded tissues of diffuse large B cell lymphoma treated with R-CHOP. *Blood*. 112;3425-33, 2008.
74. Young KH, Leroy K, Moller MB, Colleoni GW, Sanchez-Beato M, Kerbauy FR, Haioun C, Eickhoff JC, Young AH, Gaulard P, Piris MA, Oberley TD, Rehrauer WM, Kahl BS, Malter JS, Campo E, Delabie J, Gascoyne RD, Rosenwald A, Rimsza L, Huang J, Braziel RM, Jaffe ES, Wilson WH, Staudt LM, Vose JM, Chan WC, Weisenburger DD, Greiner TC. Structural profiles of TP53 mutations predict clinical outcome in diffuse large B-cell lymphoma: An international collaborative outcome study. *Blood*. 112;3088-98, 2008.
75. Salaverria I, Zettl A, Bea S, Hartmann EM, Dave SS, Wright GW, Boerma EJ, Kluijn PM, Ott G, Chan WC, Weisenburger DD, Lopez-Guillermo A, Gascoyne RD, Delabie J, Rimsza LM, Braziel RM, Jaffe ES, Staudt LM, Muller-Hermelink HK, Campo E, Rosenwald A; Leukemia and Lymphoma Molecular Profiling Project (LLMPP). Chromosomal alterations detected by comparative genomic hybridization (CGH) in subgroups of gene expression-defined Burkitt's lymphoma. *Haematologica*. 93;1327-34, 2008.
76. Lenz G, Wright G, Dave SS, Xiao W, Powell J, Zhao H, Xu W, Tan B, Goldschmidt N, Iqbal J, Vose J, Bast M, Fu K, Weisenburger DD, Greiner TC, Armitage JO, Kyle A, May L, Gascoyne RD, Connors JM, Troen G, Holte H, Kvaloy S, Dierickx D, Verhoef G, Delabie J, Smeland EB, Jares P, Martinez A, Lopez-Guillermo A, Montserrat E, Campo E, Braziel RM, Miller TP, Rimsza LM, Cook JR, Pohlman B, Sweetenham J, Tubbs RR, Fisher RI, Hartmann E, Rosenwald A, Ott G, Muller-Hermelink HK, Wrench D, Lister TA, Jaffe ES, Wilson WH, Chan WC, Staudt LM; Lymphoma/Leukemia Molecular Profiling Project. Stromal gene signatures in large B-cell lymphomas. *N Engl J Med*. 359;2313-23, 2008.
77. O'Riain C, O'Shea DM, Yang Y, Le Dieu R, Gribben JG, Summers K, Yeboah-Afari J, Bhaw-Rosun L, Fleischmann C, Mein CA, Crook T, Smith P, Kelly G, Rosenwald A, Ott G, Campo E, Rimsza LM, Smeland EB, Chan WC, Johnson N, Gascoyne RD, Reimer S, Braziel RM, Wright GW, Staudt LM, Lister TA, Fitzgibbon J. Array-based DNA methylation profiling in follicular lymphoma. *Leukemia* 23;1858-66, 2009.
78. Rosenbaum JT, Pasadhika S, Crouser ED, Choi D, Harrington CA, Lewis JA, Austin CR, Diebel TN, Vance EE, Braziel RM, Smith JR, Planck SR. Hypothesis: Sarcoidosis is a STAT1-mediated disease. *Clin Immunol* 132;174-83, 2009.
79. Mozos A, Royo C, Hartmann E, De Jong D, Baro C, Valera A, Fu K, Weisenburger DD, Delabie J, Chuang SS, Jaffe ES, Ruiz-Marcellan C, Dave S, Rimsza L, Braziel R, Gascoyne RD, Sole F, Lopez-Guillermo A, Colomer D, Staudt LM, Rosenwald A, Ott G, Jares P and Campo E. SOX11 expression is highly specific for mantle cell lymphoma and identifies the cyclin D1 negative subtype. *Haematologica* 94;1555-62, 2009.
80. Leich E, Salaverria I, Bea S, Zettl A, Wright G, Moreno V, Gascoyne RD, Chan WC, Braziel RM, Rimsza LM, Weisenburger DD, Delabie J, Jaffe ES, Lister A, Fitzgibbon J, Staudt LM, Hartmann EM, Muller-Hermelink HK, Campo E, Ott G, and Rosenwald A. Follicular lymphomas with and without translocation t(14;18) differ in gene expression profiles and genetic alterations. *Blood* 114;826-34, 2009.
81. Choi WW, Weisenburger DD, Greiner TC, Piris MA, Banham AH, Delabie J, Braziel RM, Geng H, Iqbal J, Lenz G, Vose JM, Hans CP, Fu K, Smith LM, Li M, Liu Z, Gascoyne RD, Rosenwald A, Ott G, Rimsza LM, Campo E, Jaffe ES, Jaye DL, Staudt LM, Chan WC. A new immunostain algorithm classifies diffuse large B-cell lymphoma into molecular subtypes with high accuracy. *Clin Cancer Res* 15;5494-502, 2009.



82. Wilkinson ST, Fernandez DR, Murphy SP, Braziel RM, Campo E, Chan WC, Delabie J, Gascoyne RD, Jaffe ES, Rosenwald A, Staudt LM, Rimsza LM. Decreased MHC class II expression in diffuse large B-cell lymphoma does not correlate with CpG methylation of CIITA promoters III and IV. *Leuk Lymphoma* 50;1875-8, 2009.
83. Sweetenham JW, Goldman B, LeBlanc ML, Cook JR, Tubbs RR, Press OW, Maloney DG, Fisher RI, Rimsza LM, Braziel RM, and Hsi ED. Prognostic value of regulatory T-cells, lymphoma-associated macrophages and MUM-1 expression in follicular lymphoma treated before and after the introduction of monoclonal antibody therapy: a Southwest Oncology Group study. *Ann Oncol.* 21;1196-1202, 2010.
84. Davis RE, Ngo VN, Lenz G, Tolar P, Young RM, Romesser PB, Kohlhammer H, Lamy L, Zhao H, Yang Y, Xu W, Shaffer AL, Wright G, Xiao W, Powell J, Jiang JK, Thomas CJ, Rosenwald A, Ott G, Muller-Hermelink HK, Gascoyne RD, Connors JM, Johnson NA, Rimsza LM, Campo E, Jaffe ES, Wilson WH, Delabie J, Smeland EB, Fisher RI, Braziel RM, Tubbs RR, Cook JR, Weisenburger DD, Chan WC, Pierce SK, Staudt LM. Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma. *Nature.* 463;88-92, 2010.
85. Steidl C, Lee T, Shah SP, Farinha P, Han G, Nayar T, Delaney A, Jones SJ, Iqbal J, Weisenburger DD, Bast MA, Rosenwald A, Muller-Hermelink HK, Rimsza LM, Campo E, Delabie J, Braziel RM, Cook JF, Tubbs RR, Jaffe ES, Lenz G, Connors JM, Staudt LM, Chan WC, Gascoyne RD. Tumor-associated macrophages and survival in classic Hodgkin's lymphoma. *New Engl J Med.* 362;875-85, 2010.
86. Hartmann EM, Campo E, Wright G, Lenz G, Salaverria I, Jares P, Xiao W, Braziel RM, Rimsza LM, Chan WC, Weisenburger DD, Delabie J, Jaffe ES, Gascoyne RD, Dave SS, Mueller-Hermelink HK, Staudt LM, Ott G, Bea S, Rosenwald A: Pathway discovery in mantle cell lymphoma by integrated analysis of high resolution expression and copy number profiling. *Blood.* 116;953-961, 2010.
87. Kelemen K, White CR, Gatter K, Braziel RM, Fan G. Immunophenotypic correlation between skin biopsy and peripheral blood findings in mycosis fungoides. *Am J Clin Pathol.* 134;739-48, 2010.
88. Kelemen K, Braziel RM, Gatter K, Bakke TC, Olson S, Fan G. Immunophenotypic variations of Burkitt lymphoma. *Am J Clin Pathol.* 134;127-38, 2010.
89. Meyer PN, Fu K, Greiner TC, Smith LM, Delabie J, Gascoyne RD, Ott G, Rosenwald A, Braziel RM, Campo E, Vose JM, Lenz G, Staudt LM, Chan WC, Weisenburger DD. Immunohistochemical methods for predicting cell of origin and survival in patients with diffuse large B-cell lymphoma treated with rituximab. *J Clin Oncol.* 29;200-207, 2011.
90. Ngo VN, Young RM, Schmitz R, Jhavar S, Xiao W, Lim KH, Kohlhammer H, Xu W, Yang Y, Zhao H, Shaffer AL, Romesser P, Wright G, Powell J, Rosenwald A, Muller-Hermelink HK, Ott G, Gascoyne RD, Connors JM, Rimsza LM, Campo E, Jaffe ES, Delabie J, Smeland EB, Fisher RI, Braziel RM, Tubbs RR, Cook JR, Weisenburger DD, Chan WC, Staudt LM. Oncogenically active MYD88 mutations in human lymphoma. *Nature.* 470;115-119, 2011.
91. Meyer PN, Fu K, Greiner T, Smith L, Delabie J, Gascoyne R, Ott G, Rosenwald A, Braziel R, Campo E, Vose J, Lenz G, Staudt L, Chan W, Weisenburger DD. The stromal marker SPARC predicts for survival in patients with diffuse large B-cell lymphoma treated with rituximab. *Amer J Clin Pathol.* 135;54-61, 2011.
92. Rimsza Lisa M, Wright G, Schwartz M, Chan WC, Jaffe ES, Gascoyne RD, Campo E, Rosenwald A, Ott G, Cook JR, Tubbs RR, Braziel RM, Delabie J, Miller TP, Staudt LM. Accurate classification of diffuse large B cell lymphoma into germinal center and activated B cell subtypes using a nuclease protection assay on formalin fixed paraffin embedded tissues. *Clin Cancer Res* 17;3727-3732, 2011.
93. Dunlap J, Kelemen K, Leeborg N, Braziel R, Olson S, Press R, Huang J, Gatter K, Loriaux M, Fan G. Association of JAK2 mutation status and cytogenetic abnormalities in myeloproliferative neoplasms and myelodysplastic/myeloproliferative neoplasms. *Am J Clin Pathol* 135;709-19, 2011.
94. Cardesa-Salzman TM, Colomo L, Gutierrez G, Chan WC, Weisenburger D, Climent F, Gonzalez-Barca E, Mercadal S, Arenillas L, Serrano S, Tubbs R, Delabie J, Gascoyne RD, Connors JM, Mate JL, Rimsza L, Braziel R, Rosenwald A, Lenz G, Wright G, Jaffe ES, Staude L, Jares P, Lopez-Guillermo A, Campo E. High microvessel density determines a poor outcome in patients with diffuse large B-cell lymphoma treated with rituximab plus chemotherapy. *Haematologica* 96;996-1001, 2011.

95. Leich E, Zamo A, Horn H, Haralambieva E, Puppe B, Gascoyne RD, Chan WC, Braziel RM, Rimsza LM, Weisenburger DD, Delabie J, Jaffe E, Fitzgibbon J, Staudt LM, Mueller-Hermelink HK, Calaminici M, Campo E, Ott G, Hernandez L, and Rosenwald A. MicroRNA profiles of t(14;18)-negative follicular lymphomas support a late germinal center B-cell-like phenotype. *Blood* 118(20):5550-8, 2011.
96. Iqbal J, Meyer PN, Smith LM, Johnson NA, Vose JM, Greiner TC, Connors JM, Staudt LM, Rimsza L, Jaffe E, Rosenwald A, Ott G, Delabie J, Campo E, Braziel RM, Cook JR, Tubbs RR, Gascoyne RD, Armitage JO, Weisenburger DD, and Chan WC. BCL2 predicts survival in germinal center B-cell-like diffuse large B-cell lymphoma treated with CHOP-like therapy and Rituximab. *Clin Cancer Res* 17(24):7785-7795, 2011.
97. Ramkumar HL, Shen DF, Tuo J, Braziel RM, Coupland SE, Smith JR, Chan CC. The IL-10-1082 SNP and IL-10 in CNS and vitreoretinal lymphomas. *Graefes Arch Clin Exp Ophthalmol* 250:1541-1548, 2012
98. Kelemen K, Kovacsovics T, Braziel R, Corless C, Beadling C, Fan G. RAS mutations in therapy-related acute myeloid leukemia after successful treatment of acute promyelocytic leukemia. *Leuk Lymphoma* 53:999-1002, 2012.
99. Persky DO, Dornan D, Goldman B, Braziel R, Fisher R, LeBlanc M, Maloney DG, Press O, Miller T, Rimsza LM. Fc gamma receptor 3a genotype predicts overall survival in follicular lymphoma patients treated on SWOG trials with combined monoclonal antibody plus chemotherapy but not chemotherapy alone. Epub ahead of print 01/22/2012. *Haematologica* 97:937-42, 2012.
100. Iqbal J, Shen Y, Liu Y, Fu K, Jaffe ES, Liu C, Liu Z, Lachel CM, Deffenbacher K, Greiner TC, Vose JM, Bhagavathi S, Staudt LM, Rimsza L, Rosenwald A, Ott G, Delabie J, Campo E, Braziel RM, Cook JR, Tubbs RR, Gascoyne RD, Armitage JO, Weisenburger DD, McKeithan TW, Chan WC. Genome-wide miRNA profiling of mantle cell lymphoma reveals a distinct subgroup with poor prognosis. *Blood* 119:4939-48, 2012.
101. Dunlap J, Beadling C, Warrick A, Neff T, Fleming WH, Loriaux M, Heinrich MC, Kovacsovics T, Kelemen K, Leeborg N, Gatter K, Braziel RM, Press R, Corless CL, Fan G. Multiplex high-throughput gene mutation analysis in acute myeloid leukemia. Epub ahead of print, 06/01/2012. *Hum Pathol*, 43:2167-76, 2012.
102. Johnson NA, Slack GW, Savage KJ, Connors JM, Ben-Neriah S, Rogic S, Scott DW, Tan KL, Steidl C, Horsman DE, Sehn LH, Chan WC, Iqbal J, Meyer P, Lenz G, Wright G, Rimsza LM, Valentino V, Brunhoeber P, Grogan TM, Braziel RM, Cook JR, Tubbs RR, Weisenburger DD, Campo E, Rosenwald R, Ott G, Delabie J, Holcroft C, Jaffe ES, Staudt LM, Gascoyne RD. Concurrent expression of MYC and BCL2 in diffuse large B cell lymphoma treated with Rituximab plus cyclophosphamide, doxorubicin, vincristine and prednisone. Epub ahead of print 07/30/2012. *J Clin Oncol*, 30:3452-9, 2012.
103. Schmitz R, Young RM, Ceribelli M, Jhavar S, Xiao W, Zhang M, Wright G, Shaffer AL, Hodson DJ, Buras E, Liu X, Powell J, Yang Y, Xu W, Zhao H, Kohlhammer H, Rosenwald A, Kluin P, Muller-Hermelink HK, Ott G, Gascoyne RD, Connors JM, Rimsza LM, Campo E, Jaffe ES, Delabie J, Smeland EB, Olgwang MD, Reynolds SJ, Fisher RI, Braziel RM, Tubbs RR, Cook JR, Weisenburger DD, Chan WC, Pittaluga S, Wilson W, Waldmann TA, Rowe M, Mbulaiteye SM, Rickinson AB, Staudt LM. Burkitt lymphoma pathogenesis and therapeutic targets from structural and functional genomics. *Nature*, 490:116-20, 2012.
104. Perry AM, Meyer PN, Cardesa-Salzman TM, Colomo L, Smith LM, Fu K, Greiner TC, Delabie J, Gascoyne RD, Rimsza LM, Jaffe ES, Ott G, Rosenwald A, Braziel RM, Tubbs R, Cook JR, Staudt LM, Connors JM, Vose JM, Lopez-Guillermo A, Campo E, Chan WC, Weisenburger DD. A new biological model based on immunohistochemistry predicts survival in patients with diffuse large B-cell lymphoma. *Blood*, 120:2290-6, 2012.
105. Press OW, Unger JM, Rimsza LM, Friedberg JW, LeBlanc M, Czuczman MS, Kaminski M, Braziel RM, Spier C, Gopal AK, Maloney DG, Cheson BD, Dakhil S, Miller TP, Fisher RI. Phase III randomized intergroup trial of CHOP plus rituximab compared with CHOP chemotherapy plus (131)iodine-tositumomab for previously untreated follicular non-Hodgkin lymphoma: SWOG S0016. *J Clin Oncol*, 31:314-20, 2013.
106. Valentino C, Kendrick S, Johnson N, Gascoyne R, Chan WC, Weisenburger D, Braziel R, Cook JR, Tubbs R, Campo E, Rosenwald A, Ott G, Delabie J, Jaffe E, Zhang W, Brunhoeber P, Nitta H, Grogan T, and Rimsza L. Colorimetric in-situ hybridization identifies MYC gene signal clusters correlating with increased copy number, mRNA, and protein in diffuse large B-cell lymphoma. *Amer J Clin Pathol*, 139:242-54, 2013.
107. Enjuanes EN, Albero R, Clot G, Navarro A, Bea S, Pinyol M, Martin-Subero JI, Klapper W, Staudt LM, Jaffe ES,

- Rimsza L, Braziel RM, Delabie J, Cook JR, Tubbs RR, Gascoyne R, Connors JM, Weisenburger DD, Greiner TC, Chan JC, Lopez-Guillermo A, Rosenwald A, Ott G, Campo E, Jares P. Genome-wide methylation analyses identify a subset of mantle cell lymphoma with a high number of methylated CpGs and aggressive clinicopathological features. *Int J Cancer*. 133:2852-63, 2013.
108. Press OW, Unger JM, Rimsza LM, Friedberg JW, LeBlanc M, Czuczman MS, Kaminski M, Braziel RM, Spier C, Gopal AK, Maloney DG, Cheson BD, Dakhil SR, Miller TP, Fisher RI. A comparative analysis of prognostic factor models for follicular lymphoma based on a Phase III Trial of CHOP-Rituximab + <sup>131</sup>Iodine-Tositumomab. *Clin Cancer Res*. 19:6624-32, 2013.
109. Bodor C, Grossmann V, Popov N, Okosun J, O’Riain C, Tan K, Marzec M, Araf S, Wang J, Lee AM, Clear A, Montoto S, Matthews J, Iqbal S, Rajnai H, Rosenwald A, Ott G, Campo E, Rimsza LM, Smeland EB, Chan WC, Braziel RM, Staudt LM, Wright G, Lister TA, Elemento O, Hills RK, Gribben J, Chelala C, Matolcsy A, Kohlmann A, Haferlach T, Gascoyne RD, Fitzgibbon J. *EZH2* mutations are frequent and represent an early event in follicular lymphoma. *Blood*. 122:3165-8, 2013.
110. Huang X, Meng B, Iqbal J, Ding B, Perry AM, Cao W, Smith LM, Bi C, Jiang C, Greiner TC, Weisenburger DD, Rimsza L, Rosenwald A, Ott G, Delabie J, Campo E, Braziel R, Gascoyne R, Cook J, Tubbs R, Jaffe E, Armitage J, Vose J, Staudt L, McKeithan TW, Chan W, Ye H, Fu K. Activation of the STAT3 signaling pathway predicts poor survival in diffuse large B-cell lymphoma patients treated with R-CHOP. *J Clin Oncol*. 31:4520-8, 2013.
111. Smith SD, Chan A, Spurgeon S, Okada C, Fan G, Dunlap J, Braziel R, Maziarz R. Diffuse large B-cell lymphoma in adults aged 75 year and older: a single institution analysis of cause-specific survival and prognostic factors. *Ther Adv Hematol*. 4:349-53, 2013.
112. Bouska A, McKeithan TW, Deffenbacher KE, Lachel C, Wright GW, Iqbal J, Smith LM, Zhang W, Kucuk C, Rinaldi A, Bertoni F, Fitzgibbon J, Fu K, Weisenburger DD, Greiner TC, Dave BJ, Gascoyne RD, Rosenwald A, Campo E, Rimsza LM, Delabie J, Jaffe ES, Braziel RM, Connors J, Staudt LM, Chan WC. Genome-wide copy number analyses reveal genomic abnormalities involved in transformation of follicular lymphoma. *Blood*. (Epub 2013 Sept). *Blood* 123(11): 1681-1690, 2014.
113. Scott DW, Wright GW, Williams PM, Lih CJ, Walsh W, Jaffe ES, Rosenwald A, Campo E, Chan WC, Connors JM, Smeland EB, Mottok A, Braziel RM, Ott G, Delabie J, Tubbs RR, Cook JR, Weisenburger DD, Greiner TC, Glinzmann-Gibson BJ, Fu K, Staudt LM, Gascoyne RD, Rimsza LM. Determining cell-of-origin subtypes of diffuse large B-cell lymphoma using gene expression in formalin-fixed paraffin embedded tissue. *Blood*. Epub 2014 Jan 7. 123(8):1214-17, 2014.
114. Yang Y, Schmitz R, Mitala JJ Jr, Whiting A, Xiao W, Ceribelli M, Wright GW, Zhao H, Yang Y, Xu W, Rosenwald A, Ott G, Gascoyne RD, Connors JM, Rimsza LM, Campo E, Jaffe ES, Delabie J, Smeland EB, Braziel RM, Tubbs RR, Cook JR, Weisenburger DD, Chan WC, Wiestner A, Kruhlak MJ, Iwai K, Bernal F, Staudt LM. Essential role of the linear ubiquitin chain assembly complex in lymphoma revealed by rare germline polymorphisms. *Cancer Discov*. (Epub 2014 Feb 3)
115. Iqbal J, Wright G, Wang C, Rosenwald A, Gascoyne RD, Weisenburger DD, Greiner TC, Smith L, Guo S, Wilcox RA, Teh BT, Lim ST, Tan SY, Rimsza LM, Jaffe ES, Campo E, Martinez A, Delabie J, Braziel RM, Cook JR, Tubbs RR, Ott G, Geissinger E, Gaulard P, Piccaluga PP, Pileri SA, Au WY, Nakamura S, Seto M, Berger F, de Leval L, Connors JM, Armitage J, Vose J, Chan WC, Staudt LM. Gene expression signatures delineate biologic and prognostic subgroups of peripheral T-cell lymphoma. *Blood*. (Epub 2014 March 14)
116. Iqbal J, Shen Y, Huang X, Liu Y, Wake L, Liu C, Deffenbacher K, Lachei CM, Wang C, Rohr J, Guo S, Smith LM, Wright G, Bagvati S, Kybkaer K, Fu K, Greiner TC, Vose JM, Jaffe E, Rimsza L, Rosenwald A, Ott G, Delabie J, Campo E, Braziel RM, Cook JR, Tubbs RR, Armitage JO, Weisenburger DD, McKeithan TW, Staudt LM, Gascoyne RD, Chan WC. Global microRNA expression profiling uncovers molecular markers for classification and prognosis in aggressive B-cell lymphomas. Submitted to *Blood*, March, 2013.

#### Chapters:

1. Cossman J, Neckers, LM, Braziel, R., Bakhshi, A., Arnold, A., and Korsmeyer, S.: Induction of differentiation in B cell leukemias. In Bernard, A., Boumsell, L., Dausset, J., Milstein, C., and Schlossmon, S. F. (Eds.): Leucocyte Typing. Springer-Verlag, 1984.
2. Jaffe ES, Cossman J, Neckers LM, Braziel RM, and Simrell CR: Immunologic phenotype of non-Hodgkin's lymphomas: Correlation with morphology and function. In: Cavalli, F (Ed) Malignant Lymphomas and Hodgkin's Disease: Experimental and Therapeutic Advances. Martinus Nijhoff, Boston, pp. 25-36, 1985.
3. Braziel RM, Hsu SM, and Jaffe ES: Lymph nodes, spleen, and thymus. In Spicer, S. S. (Ed): Histochemistry In Pathologic Diagnosis. Marcel Dekker, Inc., New York/Basel, 1986.
4. Braziel RM and Sacker A: Gene rearrangements in malignant lymphomas. In: Dana, B. (Ed.) Malignant Lymphomas. Kluwer Academic Publishers, Cancer Treat Res 66:147-65, 1993.
5. Perkins ML, Odell JM, and Braziel RM: Introduction to leukemia and the acute leukemias. In: Harmening, DM. (Ed.) Clinical Hematology and Fundamentals of Hemostasis. F.A. Davis Company, Publishers, 1995.
6. Braziel RM and Fan G: Molecular diagnosis of B-cell lymphoma. In: Leonard, DGB (Ed.) Molecular Pathology in Clinical Practice. Springer Sciences+Business Media, LLC, pp. 349-364, 2007.
7. Cruz F, Gatter K, and Braziel RM: Introduction to leukemia and the acute leukemias. In: Harmening, DM. (Ed.) Clinical Hematology and Fundamentals of Hemostasis. 2008.
8. Braziel R, Fan G, Leeborg N, and Dunlap J: Molecular diagnosis of B-cell malignancies. In: Schriver, I (Ed) Molecular Pathology in Clinical Practice. Springer Sciences+Business Media, LLC, 2012.

#### Abstracts:

1. Cossman, J., Braziel, R., Neckers, L., Bakhshi, A., and Korsmeyer, S.: Induction of differentiation in chronic lymphocytic leukemia. *Blood* 60 (Suppl. 1): 370, 1982.
2. Levine, R., Braziel, R., Jaffe, E., Wesley, M., and Fisher, R.: Prognosis of non-Hodgkin's lymphoma patients presenting with skin involvement. *Proc. ASCO*, 1983.
3. Cossman, J., Braziel, R., Neckers, L., Bakhshi, A., and Korsmeyer, S.: Differentiation in well-differentiated lymphocytic lymphoma/chronic lymphocytic leukemia. *Lab. Invest.* 48: 18A, 1983.
4. Braziel, R. M., Neckers, L. M., Jaffe, E. S., and Cossman, J.: Follicular (nodular) B-cell lymphomas: immunoregulation of immunoglobulin secretion. *Blood* 62: (Suppl. 1) 187a, 1983.
5. Braziel, R. M., Neckers, L. M., Jaffe, E. S., and Cossman, J.: Follicular (nodular) B-cell lymphomas: Immunoregulation of immunoglobulin secretion. *Lab. Invest.* 50: 6A, 1984.
6. Traweek, S. T., Suwanjindar, P., Bakke, A. C., and Braziel, R.M.: Characterization of lineage expression in TdT-positive acute myelogenous leukemia. *Mod Pathol* 1:562, 1988.
7. Braziel, R. M., Carter, A., McCall, E., Moon, S., Heinrich, M., and Bagby, G.: Regulation of B-cell differentiation by IL-1 induced stromal cells: IL-6 alone does not induce immunoglobulin secretion. *Blood* 72:(suppl 1)543a, 1988.
8. Braziel, R. M., Suwanjindar, P., Moon, S., Bagby, G., and Bakke, A. C.: Induction of terminal differentiation of B-lymphoma cells: Role of IL-6. *Mod Pathol* 2: 12A, #68, 1989.
9. Traweek, T. and Braziel, R. M.: In Vitro response of T-cell antigen positive AMLL to differentiation inducing agents. *Mod Pathol* 2:97A, #577, 1989.
10. Braziel, R., Traweek, T., Suwanjindar, P., and Bakke T.: CD7-positive acute mixed lineage leukemia (AMLL): Committed myeloid progenitor cells. *Blood* 74:(suppl 1)56A, 1990.
11. Braziel, R., Suwanjindar, P., Traweek, T., and Bakke, T.: CD7 + acute mixed lineage leukemias (AMLL):

Malignancies of committed myeloid progenitor cells. *Mod Pathol* 3:11A, #57, 1990.

12. Gonzalez, C., Medeiros, L. J., Brazier, R., Ruxer, R., and Jaffe, E. S.: Peripheral T-cell lymphoma involving subcutaneous adipose tissue associated with hemophagocytic syndrome: A report of five cases. *Mod Pathol* 3:38A, #217, 1990.
13. Brazier, R., Grogan, T., Berman, M., von Borstel, R., Stanton, S., Beckstead, J., Suwanjindar, P., and Cossman, J.: BCL-2: JH Translocation in follicular lymphoid hyperplasia. *Mod Pathol* 4:68A, #398, 1991.
14. Grogan, T., Spier, C., Brazier, R., Wirt, D., Montiel, M., Kerrigan, D., Banks, P., Kjeldsberg, C., Nathwani, B., Schnitzer, B., Tubbs, R., Levy, N., Cossman, J., Berman, M., Fisher, R., Miller, T. SWOG: Refined working formulation (WF) categorization of lymphomas using phenotypic and genotypic analyses: A SWOG central repository study. *Mod Pathol* 4:73A, #425, 1991.
15. Sanguenza, O., White, C., Suwanjindar, P., and Brazier, R.: Mycosis fungoides (MF): An immunologic panel for routine diagnosis. *Modern Pathology* 5:31A, #178, 1992.
16. Sanguenza O., Suwanjindar, P., and Brazier, R.: Peripheral blood evaluation in patients with mycosis fungoides (MF). *Mod Pathol* 5:34A, #191, 1992.
17. Hammer, E., Sanguenza, O., White, C., Suwanjindar, P., and Brazier, R.: Immunophenotypic and genotypic analysis in cutaneous lymphoid hyperplasia (CLH). *Mod Pathol* 5:34A, #192, 1992.
18. Guinee Jr., D., von Borstel, R., Zutter, M., and Brazier, R.: JH/BCL- 2 translocations and BCL-2 protein expression in hyperplastic tonsils. *Mod Pathol* 5:78A, #456, 1992.
19. Hammer, E., Suwanjindar, P., and Brazier, R.: Molecular analysis of CD3(+) and CD3(-) peripheral T-cell lymphomas (PTCL). *Mod Pathol* 5:78A, #458, 1992.
20. Grogan T., Brazier R., Banks, P., Foucar K., Levy, N., Nathwani, B., Tubbs, R., Kjeldsberg, C., Schnitzer, R., Spier, C., and Miller, T.: The proliferative rate of aggressive non-Hodgkin's lymphomas identifies a patient group with fatal disease: A prospective Southwest Oncology Group trial. *Mod Pathol* 6:91A, #525, 1993.
21. Sacker, A., Suwanjindar, P., and Brazier, R.: Molecular genetic analysis of polyclonal B-cell lymphocytosis. *Mod Pathol* 6:99A, #592, 1993.
22. Fandel, T., Sprague, J., Zutter, M., and Brazier, R.: Bcl-2 protein expression in atypical follicular hyperplasias. *Mod Pathol* 6:89A, #513, 1993.
23. Sanguenza, O.P. and Brazier, R.M.: Bcl-2 protein expression in cutaneous lymphoid hyperplasias and follicular hyperplasia of the skin. *Mod Pathol* 7:49A, #270, 1994.
24. Mongeon, C.A., Brazier, R.M., Leith, C.P., and Foucar, K.: Rapidly fatal multisystem polyclonal immunoblastic (IB) proliferations: A clinical, phenotypic, and molecular analysis. *Mod Pathol* 7:116A, #675, 1994.
25. Grogan, T., Kjeldsberg, C., Tubbs, R., Dahlberg, S., Brazier, R., Foucar, C. Leith, C., Spier, C. Gaynor, E., Miller, T., and Fisher, R., (The SWOG Central Lymphoma Repository): A Southwest Oncology Group (SWOG) Clinical Analysis of Anaplastic Large Cell Lymphoma (ALCL) in the Revised European American Lymphoma (REAL) Classification. *Mod Pathol* 8:111A, #644, 1995.
26. Grogan, T., Miller, T., Dahlberg, S., Brazier, R., Banks, P., Nathwani, C., Kjeldsberg, C., Tubbs, R., Foucar, K., Leith, C., Spier, C., Schnitzer, B., Gulley, P.: Morphologic review of 2100 SWOG patients supports the REAL classification of lymphoma as clinically useful. *Mod Pathol* 9: 1996.
27. Galloway, J., Brazier, R. M., Sanguenza, O.P.: Absence of HTLV-1 and HTLV-2 in lymphomatoid papulosis. *Mod Pathol* 10:44A, #240, 1997.
28. Neuwelt, E.A., Wilson, D.J., Druker, D.J., Rosenbaum, J.T., Shults, W.T, McAllister, L.D., Brazier, R.M., Coleman, R.D., and Doolittle, N.D.: Does an ocular or CSF sanctuary contribute to the late recurrence of primary non-AIDS CNS lymphoma: The OHSU experience. ASCO, May, 1998.

29. Braziel, R.M., Arber, D., Miller, T., Fisher, R., and Grogan, T.: Burkitt-like lymphoma: A distinctive morphology and phenotype with poor prognosis. A Southwest Oncology Group Study. *Mod Pathol* 12:132A, #771, 1999.
30. Parks, S.B., Braziel, R.M., Popovich, B., and Press, R.: Quantitative real-time Bcr-Abl rt-PCR for the management of t(9;22) positive leukemias. Presented at 2000 AMP meeting, Denver, CO. *J Mol Diag* 2:(suppl) pg 227, #H17, 2000.
31. Smith, J.R., Braziel, R.M., Neuwelt, E.A., and Rosenbaum, J.T.: Expression of B-lymphocyte chemoattractant by dendritiform cells, as well as malignant lymphocytes, in primary central nervous system lymphoma. Poster presentation at 2000 ASH meeting. *Blood* 96:(Suppl) 333a, #1437, 2000.
32. Mauro, M.J., Druker, B.J., Braziel, R.M., Launder, T.M., Ford, J., and O'Dwyer, M.E.: Dose response effect and time to clinical response in patients with interferon-refractory CML treated with STI571. Poster presentation at 2000 ASH meeting. *Blood* 96:(Suppl) 735a, #3179, 2000.
33. Launder, T.M., Druker, B.J., Mauro, M.J., O'Dwyer, M.E., Resta, D., and Braziel, R.M.: Morphologic findings in peripheral blood and bone marrow of STI571-treated chronic myelogenous leukemia patients. Poster presentation at 2000 ASH meeting. *Blood* 96:(Suppl) 735a, #3177, 2000.
34. Miller, T.P., Grogan, T.M., Unger, J., Braziel, R.M., Jaramillo, M. Fisher, R.I.: Cellular proteins determined by immunohistochemistry predict outcome in patients with aggressive non-Hodgkin's lymphoma: A first generation model of risk. Poster presentation at 2001 ASH meeting. *Blood* 98: (Suppl) 125a, #526, 2001.
35. Press, R. D., Braziel, R.M., Magenis, R. E., Schnell, J.L., Roselle, A.A., Parks, S.B., Ries, R.E., Tran, T.C., Loriaux, M.M., Resta, D.J. and Druker, B.J.: Bcr-Abl RNA levels (by quantitative RT-PCR) correlate with cytogenetic detection of the t(9;22) in STI571-treated leukemic patients. Poster presentation at 2001 ASH meeting. *Blood* 98: (Suppl) 614a, #2574, 2001.
36. Press, O., Unger, U., Braziel, R.M., Maloney, D., LeBlanc, M., Miller, T.P., Fisher, R.I.: A phase II trial of CHOP followed by Bexxar(Tositumomab and Iodine-131-Tositumomab) for treatment of newly diagnosed follicular non-Hodgkin's lymphomas (SWOG 9911). Platform presentation at 2001 ASH meeting. *Blood* 98: (Suppl) 843a, #3504, 2001.
37. Maloney, D.G., Press, O., Braziel, R.M., Unger, J., LeBlanc, M., Miller, T.P., and Fisher, R.I.: A phase II trial of CHOP followed by Rituximab chimeric monoclonal anti-CD20 antibody for treatment of newly diagnosed follicular non-Hodgkin's lymphoma: SWOG 9800. Platform presentation at 2001 ASH meeting. *Blood* 98: (Suppl) 843a, #3502, 2001.
38. Fan, G., Braziel, R.M., Bagg, A., Arber, D.A.: Progress towards standardization: Comparison of JH/Bcl-2 testing in a large multicenter study. Poster presentation at 2002 USCAP annual meeting. *Mod Pathol* 15:240A, #1001, 2002.
39. Fan, G., Braziel, R.M., Grogan, T.: Failure of beta-globin gene detection does not predict non-amplification of DNA in JH/Bcl-2 PCR analysis: Insights from a national follicular lymphoma clinical trial. Platform presentation at 2002 USCAP annual meeting. *Mod Pathol* 15:240A, 1002, 2002.
40. Huang, J.Z., Greiner, T.C., Weisenburger, D.D., Braziel, R.M., Chan, W.C.: Analysis of immunoglobulin light chain gene expression in B-cell lymphomas by cDNA microarray. Poster presentation at 2002 USCAP annual meeting. *Mod Pathol* 15:244A, #1020, 2002.
41. Chu, A.Y., Paessler, M.E., Braziel, R.M., Arber, D.A., Bijwaard, K.E., Bagg, A.: Immunoglobulin heavy chain gene analysis in lymphomas: A multicenter study demonstrating the heterogeneity of performance of polymerase chain reaction assays. Presented at 2002 USCAP annual meeting. *Mod Pathol* 15:235A, #985, 2002.
42. Miller, T., LeBlanc, M. Braziel, R., Grogan, T., Press, O., Fisher, R.: Was the bimodal age incidence of Hodgkin's lymphoma a result of mistaken diagnoses of non-Hodgkin's lymphoma? Presented at 2002 ASH annual meeting. *Blood* 100: 771a, #3048, 2002.
43. Yee, K.W.H, Braziel, R.M., O'Farrell, A.M., McGreevey, L.S., Haley, A., Town, A.R., Griffith, D.J., Cherrington, J.M., Heinrich, M.C.: SU11248 inhibits activation loop mutants of FLT3. Presented at 2002 ASH annual meeting.

Blood 100: 739a, #2922, 2002.

44. Miller, T.P., LeBlanc, M., Grogan, T.M., Braziel, R.M., Staudt, L.L., Fisher, R.I.: Major histocompatibility complex (MHC) class II antigen HLA-DR gene expression levels in diffuse large B-cell lymphoma correlate with survival. Presented at 2002 ASH annual meeting. Blood 100: 346a, #1340, 2002.
45. Huang, J., Hook, R., Fan, G., Gatter, K., Rodgers, W., Braziel, R.: Microarray gene expression data can be efficiently managed and mined with Microsoft Access and Excel. Presented at 2003 USCAP annual meeting. Mod Pathol 16:323A, #1477, 2003.
46. Rimsza, L., LeBlanc, M., Braziel, R., Jaramillo, M., Miller, T.P., Staudt, L., Grogan, T., Fisher, R.: Loss of major histocompatibility complex (MHC) class II antigen gene expression predicts poor survival in diffuse large B-cell lymphoma (DLBCL). Presented at 2003 USCAP annual meeting. Mod Pathol 16:250A, #1141, 2003.
47. Greiner TC, Smith MS, Rosenwald A, Weisenburger DW, Gascoyne R, Connor J, Delabie J, Campo E, Ott G, Mueller-Hermelink K, Braziel RM, Jaffe ES, Armitage JO, Staudt LM, and Chan WC. p53 in diffuse large B-cell lymphoma. Oral presentation at 2003 ASH annual meeting. Blood 102; 368a: #1338, 2003.
48. Press OW, Unger JM, Braziel RM, Maloney DM, Miller TP, LeBlanc M, and Fisher RI. CHOP followed by Tositumomab/Iodine I 131 Tositumomab (Bexxar) for treatment of newly diagnosed follicular non-Hodgkin's lymphomas: A phase II trial of the Southwest Oncology Group (S9911). Oral presentation at 2003 ASH annual meeting. Blood 102; 29a: #90, 2003.
49. Rosenwald A, Wright G, Leroy K, Yu X, Gaulard P, Gascoyne RD, Chan WC, Zhao T, Haioun C, Greiner TC, Weisenburger DD, Lynch JC, Vose JM, Armitage JO, Smeland EB, Kvaloy S, Holte H, Delabie J, Campo E, Montserrat E, Lopez-Guillermo A, Ott G, Muller-Hermelink HK, Connors JM, Braziel RM, Grogan TM, Fisher RI, Miller TP, LeBlanc M, Chiorazzi M, Zhao H, Yang L, Powell J, Wilson WH, Jaffe ES, Simon R, Klausner RD, and Staudt LM, for the LLMPP. Molecular diagnosis of primary mediastinal B cell lymphoma identifies a clinically favorable subgroup of diffuse large B cell lymphoma related to Hodgkin lymphoma. Oral presentation at 2003 ASH annual meeting. Blood 102; 62a: #208, 2003.
50. Rimsza L, Roberts R, Miller T, Unger J, LeBlanc M, Braziel R, Weisenburger D, Chan WC, Greiner T, Muller-Hermelink K, Jaffe E, Gascoyne RD, Campo E, Fuchs D, Spier C, Fisher R, Staudt L, and Grogan T. Loss of MHC class II (MHCH) gene and protein expression in diffuse large B cell lymphoma is related to decreased tumor immunosurveillance and poor patient survival: A follow-up study to the NIH Director's Challenge Leukemia and Lymphoma Molecular Profiling Project (LLMPP). Poster presentation at 2003 ASH annual meeting. Blood 102; 390a: #1417, 2003.
51. Rimsza, L, Roberts R, Campo E, Grogan T, Bea S, Salaverria I, Zettl A, Fisher R, Unger J, LeBlanc M, Staudt L, Gascoyne R, Chan W, Weisenburger D, Greiner T, Jaffe E, Braziel R, Mueller-Hermelink K, and Miller T. Loss of major histocompatibility class II (MHCII) expression in nodal diffuse large B cell lymphoma (DLBCL) is highly coordinated and unlikely related to chromosomal deletions. Poster presentation at 2003 ASH annual meeting. Blood 102; 893a: #3321, 2003.
52. Iqbal J, Sanger WG, Horsman DE, Rosenwald A, Pickering DL, Dave S, Cao K, Zhu Q, Ziao L, Hans CP, Weisenburger DD, Greiner TC, Gascoyne RD, Ott G, Muller-Hermelink HK, Delabie J, Braziel RM, Jaffe ES, Campo E, Lynch J, Connors JM, Vose J, Armitage JO, Grogan T, Staudt LM, and Chan WC. BCL2 translocation defines a subset of DLBCL with germinal center B-cell-like gene expression profiles and preferential expression of a set of genes. Poster presentation at 2003 ASH annual meeting. Blood 102; 884a: #3289, 2003.
53. Hans CP, Weisenburger DD, Greiner TC, Gascoyne RD, Delabie J, Ott G, Muller-Hermelink HK, Campo E, Braziel RM, Jaffe ES, Pan Z, Farinha P, Smith LM, Falini B, Banham AH, Rosenwald A, Staudt LM, Connors JM, Armitage JO, and Chan WC. Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Oral presentation at 2003 ASH annual meeting. Blood 102; 177a: #618, 2003.
54. Dave SS, Wright G, Tan B, Rosenwald A, Chan WC, Gascoyne RD, Greiner TC, Weisenburger DD, Vose JM, Armitage JO, Braziel RM, Miller TP, Grogan TM, Fisher RI, Smeland EB, Kvaloy S, Holte H, Delabie J, Connors JM, Muller-Hermelink HK, Ott G, Davies AJ, Norton AJ, Lister TA, Campo E, Montserrat E, Wilson WH, Jaffe ES, Chiorazzi M, Zhao H, and Staudt LM, for the Lymphoma/Leukemia Molecular Profiling Project. A molecular

predictor of survival following diagnosis of follicular lymphoma. Oral presentation at 2003 ASH annual meeting. Blood 102; 177a: #617, 2003.

55. Fan G, Molstad M, Braziel RM, Rodgers W, Huang J, and Nagalla SR. Protein profiling of follicular lymphoma and Burkitt's lymphoma using SELDI protein-chip technology. Poster presentation at 2003 ASH annual meeting. Blood 102; 889a: #3307, 2003.
56. Shen J, Rosee PL, Griswold I, Heinrich MC, Braziel R, McGreevey L, Haley A, Giese N, Druker BJ, and Deininger MW. Effects of MLN518 (CT53518), a dual Flt3 and Kit inhibitor, on normal and malignant hematopoiesis. Oral presentation at 2003 ASH annual meeting. Blood 102; 139a: #476, 2003.
57. Fu K, Weisenburger DD, Greiner TC, Ott G, Delabie J, Jaffe ES, Braziel RM, Gesk S, Siebert R, Pickering DL, Dave BJ, Sanger WG, Smith LM, Muller-Hermelink HK, Campo E, Gascoyne RD, Rosenwald A, Chiorazzi M, Staudt LM, Chan WC for the Lymphoma/Leukemia Molecular Profiling Project. Cyclin D1-negative mantle cell lymphoma: a study of nine cases. Poster presentation at 2004 USCAP meeting. Mod Pathol 17:248A, #1044, 2004.
58. Huang J, Fan GF, Zhong Y, Gatter K, Braziel R, Gross G, Bakke A. Diagnostic utility of aberrant CD22 expression in differentiating neoplastic cells of small B-cell lymphoproliferative disorders from benign B-cells in immunophenotyping by four-color multiparameter flow cytometry. Poster presentation at 2004 USCAP meeting. Mod Pathol 17:251A, #1060, 2004.
59. Zu Y, Campo E, Hans CP, Weisenburger DD, Braziel R, Delabie J, Gascoyne R, Vivero A, Steinberg S, Pittaluga S, Chan WC, Jaffe ES. Validation of tissue microarray immunohistochemistry staining and interpretation in diffuse large B-cell lymphoma (DLBCL). Poster presentation at 2004 USCAP meeting. Mod Pathol 17:349A, #1477, 2004.
60. Molstad M, Nagalla S, Standley M, Braziel R, Huang J, Rodgers W, Jia H, Fan G. Identification of proteins involved in the transformation of follicular lymphoma. Poster presentation at 2004 USCAP meeting. Mod Pathol 17:261A, #1099, 2004.
61. Andres MW, Roberts RA, Mustacich DJ, Ott G, Gascoyne RD, Fuchs DA, Wang MX, Braziel RM, Chan WC, Grogan, TM, Rimsza LM. In Situ hybridization (ISH), immunohistochemistry (IHC), and gene expression profiling (GEP) for determining monoclonality in 61 cases of diffuse large B-cell lymphoma. Poster presentation at 2005 USCAP meeting. Mod Pathol 18:221A, #1027, 2005.
62. Neppalli V, Iqbal J, Dave BJ, Pickering DL, Dave S, Hans CP, Weisenburger DD, Greiner TC, Gascoyne RD, Ott G, Mueller-Hermelink HK, Sanger WG, Horsman DE, Rosenwald A, Delabie J, Braziel RM, Jaffe ES, Campo E, Lynch JC, Connors JM, Vose JM, Armitage JO, Grogan TM, Staudt LM, Chan WC. BCL2 expression as a prognostic indicator in subtypes of diffuse large B-cell lymphoma. Poster presentation at 2005 USCAP meeting. Mod Pathol 18:243A, #1127, 2005.
63. Fu K, Dave S, Wright G, Weisenburger DD, Greiner TC, Ott G, Muller-Hermelink HK, Rimsza LM, Braziel RM, Gascoyne RD, Delabie J, Campo E, Jaffe ES, Chiorazzi M, Zhao H, Chan WC, Staudt LM. Molecular diagnosis of Burkitt lymphoma using gene expression profiling. Poster presentation at 2005 USCAP meeting. Mod Pathol 18:230A, #1067, 2005.
64. Greiner T, Hacia J, Rosenwald A, Weisenburger D, Smith L, Jaffe E, Gascoyne R, Campo E, Mueller-Hermelink K, Ott G, Delabie J, Braziel R, Staudt L, Chan W. mRNA expression profile of p53 mutant or ATM mutant cases of mantle cell lymphoma. Mod Pathol 18:232A, #1077, 2005.
65. Dave SS, Fu K, Wright G, Lam L, Greiner TC, Weisenberger DD, Kluin PM, Boerma E, Rosenwald A, Ott G, Muller-Hermelink HK, Gascoyne RD, Delabie J, Rimsza LM, Braziel RM, Grogan TM, Campo E, Jaffe ES, Vose J, Armitage JO, Connors JM, Smeland EB, Kvaloy S, Holte H, Miller TP, Fisher RI, Montserrat E, Wilson WH, Bahl M, Zhao H, Yang L, Powell J, Simon R, Chan WC, Staudt LM for the Leukemia/Lymphoma Molecular Profiling Project. Gene expression distinguishes Burkitt lymphoma from other aggressive lymphomas and identifies patients who are highly curable with intensive chemotherapeutic regimens. Oral presentation at ASH 2005 annual meeting. Blood 106; 125a: #415, 2005.
66. Press OW, Unger J, Maloney D, Braziel RM, LeBlanc M, Grogan T, Miller TP, Fisher RI. An update of a phase II trial of CHOP followed by Tositumomab/Iodine I-131 Tositumomab (Bexxar) for front-line treatment of advanced



stage follicular lymphoma: Southwest Oncology Group protocol 9911. Oral presentation at ASH 2005 annual meeting. Blood 106; 107a: #352, 2005.

67. Fan G, Zhong Y, Smith C, Huang J, Brazier RM. A proteomic approach to discovery of candidate proteins involved in the transformation of follicular lymphoma. Poster presentation at ASH 2005 annual meeting. Blood 106; 289a: #9845, 2005.
68. Huang JZ, Bakke AC, Fan G, Brazier R, Gatter KM, Maziarz RT, Leis JF, Zhong Y. A novel multiparameter flow cytometric cytotoxicity assay detects p53 deletion as the major cause of In Vitro resistance to fludarabine in B-cell chronic lymphocytic leukemia. Poster presentation at ASH 2005 annual meeting. Blood 106; 195b: #4470, 2005.
69. Young KH, Leary K, Moller MB, Sanchez-Beato M, Colleoni GWB, Kerbauf FR, Koduru PPK, Haioun C, Gaulard P, Piris MA, Campo E, Delabie J, Gascoyne RD, Rosenwald A, Ott G, Huang J, Brazier RM, Jaffe ES, Staudt LM, Wilson WH, Hanehira K, Rehauer WM, Eickhoff JC, Bahi BS, Malter JS, Chan WC, Weisenburger DD, Greiner TC. Structural profiles of p53 gene mutations predict clinical outcome in diffuse large B-cell lymphoma: an international collaborative study. Poster presentation of ASH 2006 annual meeting. Blood 108; 243a: #811, 2006.

### **Invited Lectures, Conference Presentations or Professorships:**

1. Lecture: Oregon Society for Histotechnology, 1985, Portland, OR. "Technical Aspects of the Diagnosis of Malignant Lymphomas".
2. Lecture: Portland-Area Laboratory Consortium for Education, April 1986, Portland, OR. "Clinical Utility of Cell Surface Markers".
3. Lecture: Oregon State University Histochemistry Symposium, 1986, Corvallis, OR. "Clinical Applications of Immunoperoxidase Technique in Humans".
4. Lecture: Northwest Medical Laboratories Symposium, 1987, Portland, OR. "Hematologic Disease in the Elderly".
5. Lecture: St. Charles Medical Center CME Program, March 1988, Bend, OR. "Diagnosis of Lymphoproliferative Disorders".
6. Lecture: Pacific NW Pathology Assoc. Symposium, May 1989, Semi-Ah-Moo, WA. "Diagnosis of Acute Mixed Lineage Leukemias".
7. Lecture: Preuss Foundation Symposium, October 1989, Scottsdale, Arizona. "Adjunctive Studies in the Pathologic Evaluation of CNS Lymphomas".
8. Lecture: Veterans Administration Medical Center Research Conference, November 1989, Portland, OR. "Pathologic Diagnosis of Primary CNS Lymphomas".
9. Lecture: Oregon Dermatology Society Lecture, October 1991, Portland, OR. "Immunophenotyping and Genotyping of Skin Lymphoid Infiltrates".
10. Lecture: Oregon Pathologists Association Lecture, February 1991, Portland, OR. "Lymphoproliferative Disorders".
11. Lecture: SWOG Spring meeting - Lymphoma Biology Committee, April 1992, San Antonio, Texas. "J-H/Bcl-2 Translocations in Human Atypical Follicular Hyperplasias".
12. Lecture: National Meeting of American Association of Pathology Assistants, 1992, Seattle, WA. "Immunophenotypic and Genotypic Analysis of Malignant Lymphomas".
13. Lecture: SWOG Fall Meeting - Lymphoma Biology Committee, October 1992, St. Louis, MO. "J-H/Bcl-2 Translocations in Human Follicular Lymphomas and Follicular Hyperplasias".
14. Co-Chairman - Hematopathology Platform Scientific Session – US and Canadian Academy of Pathology annual meeting, New Orleans, LA, March, 1993.
15. Lecture: College of American Pathologists Workshop, April 25, 1995, Orlando, Florida. "Molecular Diagnostics in Hematopathology".
16. Lecture: Blood Brain Barrier Disruption Program National Meeting, May 5, 1995, Portland, OR. "An Update on CNS Lymphomas".
17. Lecture: Pacific NW Pathology Association Symposium, May 19-20, 1995, Salishan Lodge, Gleneden Beach, OR. "Gastrointestinal Lymphomas".
18. Lecture: College of American Pathologists Workshop, September 20, 1995, New Orleans, LA. "Molecular Diagnostics in Hematopathology".
19. Hematopathology Society Workshop case presentation, October 19, 1995, Duarte, CA. "Immunodeficiency-Related Lymphoproliferative Disorders".
20. Lecture: Association for Molecular Pathology annual meeting, November 10-12, 1995, Minneapolis, MN. Hematopathology workshop speaker, "Update on Molecular Diagnostics in Leukemias and Lymphomas".
21. Lecture: Oncology Grand Rounds, Meridian Park Hospital, January 10, 1996. "The Use of Adjunctive Studies in the Diagnosis of Malignant Lymphomas".
22. Lecture: US and Canadian Academy of Pathology - Society for Hematopathology Companion Meeting, March 24, 1996, Washington, D.C. "A Multi-Institutional Perspective: The Southwest Oncology Group (SWOG)

- Lymphoma Biology Laboratory Experience with Prognostic Markers”.
23. Co-Chairman - Hematopathology Platform Scientific Session – US and Canadian Academy of Pathology annual meeting, March 26, 1996, Washington, D.C.
  24. Moderator for Workshop on Acute Leukemias - Association for Molecular Pathology, November 13-15, 1996, Baltimore, Maryland.
  25. Lecture: Oregon Pathologists Association, September 21, 1996. “Molecular Diagnostics in Hematopathology”.
  26. Lecture: Good Samaritan Hospital Cancer Conference, Portland, OR, September 24, 1997. “Advances in Lymphoma Classification: Impact on Diagnosis, Prognosis, and Treatment”.
  27. Hematopathology Plenary Session Moderator - Association for Molecular Pathology Annual Meeting, November 12-15, 1997, San Diego, CA.
  28. Hematopathology Workshop Moderator, Association for Molecular Pathology Annual Meeting, November 12-15, 1997, San Diego, CA.
  29. Co-Chairman - Hematopathology Platform Scientific Session – US and Canadian Academy of Pathology annual meeting, March 4, 1998, Boston, Mass.
  30. Lecture: Good Samaritan Hospital Cancer Conference, Portland, OR, September 9th, 1998. “Prognostic Markers in Non-Hodgkin’s Lymphomas”.
  30. Lecture: Portland-Area Laboratory Consortium for Education, September 11, 1999, Portland, OR. "Update on Lymphoid Malignancies -Phenotypes and Genotypes”.
  31. Lecture: Association for Molecular Pathology annual meeting – Hematopathology Workshop, November 7, 1999, St. Louis, MO. “Hematopathology Molecular Diagnostics Sample Exchange Program”.
  31. Lecture: Portland-Area Laboratory Consortium for Education, September 9, 2000, Portland, OR. “The Role of Special Studies in Diagnosis of Leukemias and Lymphomas: An Update.”
  32. Lecture: Oregon Pathologists Association Seminar, October 7, 2000, Portland, OR. "Bone Marrow Pathology 2000: Update on Diagnosis of Hematologic Malignancies.”
  33. Lecture: SWOG Spring meeting - Lymphoma Biology Committee, April 2001, San Francisco, CA. "IgH/Bcl2 Nested PCR Analysis for Detection of MRD in Follicular Lymphomas: SWOG 9800”.
  34. Lecture: Oregon Spring Seminar, May 5, 2001, Eugene, OR. “Update on Hematologic Malignancies; Diagnosis of Malignant Lymphomas”.
  35. Lecture: Ninth United States – Japan Lymphoma Clinical Trials Summit, September 20, 2002, Kauai, Hawaii. “Biology of Non-Hodgkin Lymphoma”.
  36. Lecture: speaker and chair – American Society of Hematology Education Session, December 6, 2003, San Diego, CA. “Molecular Diagnostics of Hematologic Malignancies”.
  37. Lecture: Tenth Annual Neuro-Oncology and Blood-Brain Barrier Disruption Consortium Meeting, March 18, 2004, Sunriver Resort, Sunriver, OR. "State of the Art in Molecular Hematopathology of Primary CNS Lymphoma”.
  38. Lecture: 2004 Spring Seminar – Washington State Society for Clinical Laboratory Science and Northwest State Society of American Medical Technologists – April 30, 2004, Vancouver, WA. "An Update on the Role of Adjunctive Laboratory Studies in the Diagnosis and Follow-Up of Patients with Hematologic Malignancies”.
  39. Lecture: Canadian Academy of Pathology – July 2004, Montreal, Canada. "Molecular Diagnosis of Hematologic Malignancies”.
  40. Lecture: Association for Molecular Pathology Annual Meeting – November 13, 2004, Los Angeles, CA., "Is It Time to Adopt Molecular Classifications for the Primary Diagnosis of Lymphoma?”.
  41. Lecture: Training Practicum for BMS – February 2, 2011, Portland, OR. “CML Pathology: Blood and Bone Marrow Findings”.
  42. Lecture: Novartis CML Educational Practicum – March 22, 2012, Portland, OR. “Pathology in Ph (+) Leukemias”.
  43. Invited FDA Expert Panel Member: “Minimal Residual Disease Workshop”, sponsored by ASCO, AACR, and ASH. Bethesda, MD, 4/18/2012.
  44. Lecture: Association for Molecular Pathology Annual Meeting – October 25, 2012, Long Beach, CA.. "Guidelines for Interpretation of Lymphoid Clonality Testing”. Workshop presentation with Drs. Patricia Groenen and James Cook.
  45. Lecture: Novartis CML Educational Practicum – June 4, 2013, Portland, OR. “Pathology in Ph (+) Leukemias”.
  46. Lecture: Challenges in Diagnosis and Treatment of Aggressive B-cell Lymphomas – Oregon Pathologists Association Seminar, March 15, 2014, Portland, OR.
  47. Lecture: Genomics Seminar at Providence Lab – NanoString Applications in Malignant Lymphomas, April 24, 2014, Portland, OR.

#### **Honors and Awards:**

Named in The Best Doctors in America: 2013-2014.

Named in The Best Doctors in America: 2012-2013.

Named in The Best Doctors in America: 2011-2012.

Named in The Best Doctors in America: 2010-2011.  
Named in The Best Doctors in America: 2009-2010.  
Named in The Best Doctors in America: 2007-2008.  
Named in The Best Doctors in America: 2006-2007.  
Named in The Best Doctors in America: 2005-2006.  
Named in The Best Doctors in America: 2004-2005.  
Named in The Best Doctors in America: 2003-2004.  
Named in The Best Doctors in America: 2002-2003.  
Named in The Best Doctors in America: 2001-2002.  
Named in The Best Doctors in America: 1999-2000.  
Named in The Best Doctors in America: 1997-1998.  
Named in The Best Doctors in America: Pacific Region, 1996-1997.  
Tartar Trust, 1992.  
MRF Foundation Grant, 1986.  
Tartar Trust, 1985.  
Phi Beta Sigma Biology Honorary Society - 1972 - University of New Mexico.  
Graduated Magna Cum Laude in General Studies - 1972 - University of New Mexico.

## V. SERVICE

### **Membership in Professional Societies:**

Oregon Pathologists Association (OPA)  
U.S. and Canadian Academy of Pathology (USCAP)  
American Society of Hematology (ASH)  
Society for Hematopathology (SHP)  
American Society of Clinical Pathology (ASCP)  
College of American Pathologists (CAP)  
Southwest Oncology Group (SWOG)  
Association for Molecular Pathology (AMP)

### **Editorial and Ad Hoc Review Activities:**

**Associate Editor:** Journal of Molecular Diagnostics / American Journal of Pathology. 1999-2008.

### **Ad-hoc Reviewer:**

Blood  
Cancer  
Journal of Dermatopathology  
Archives of Pathology and Laboratory Medicine  
American Journal of Clinical Pathology  
American Journal of Pathology  
Mayo Clinic Proceedings  
Molecular Diagnosis  
Diagnostic Molecular Pathology  
Journal of Molecular Diagnostics  
Acta Hematologica  
Leukemia

### **Other Expert Consultant/Reviewer Activities:**

Expert reviewer, bone marrows, for national SWOG leukemia treatment protocols.  
Expert reviewer, lymphoma biopsies, for national SWOG lymphoma treatment protocols.  
USCAP Abstract Review Board, Hematopathology Section, 1996.  
USCAP Abstract Review Board, Hematopathology Section, 1997.  
USCAP Abstract Review Board, Hematopathology Section, 1998.  
NCI Special Emphasis Panel/Scientific Review Group - Spores in Leukemia/Lymphoma, October, 2003  
ASH Abstract Review Committee, 2007.  
NIH Special Emphasis Panel/Scientific Review Group – Clinical Research – Loan Repayment Program, May, 2010  
NIH Special Emphasis Panel/Scientific Review Group – Clinical Research – Loan Repayment Program, May, 2011.  
FDA Expert Panel Member: “Minimal Residual Disease Workshop”, sponsored by ASCO, AACR, and ASH. Bethesda,

MD, 4/18/2012.

NIH Special Emphasis Panel/Scientific Review Group – Clinical Research – Loan Repayment Program, May, 2012

NIH Special Emphasis Panel/Scientific Review Group – Clinical Research – Loan Repayment Program, May, 2013

NIH Clinical Assay Development Program Special Emphasis Panel – December 3, 2013.

NIH Special Emphasis Panel/Scientific Review Group – Clinical Research – Loan Repayment Program, May, 2014.

FDA – Appointed as Consultant on Hematology and Pathology Devices Panel of the Medical Devices Advisory Committee, Center for Devices and Radiological Health, Food and Drug Administration. October, 2013 – present.

### **Committees/University Activities:**

#### International/National/Regional

##### **Southwest Oncology Group**

- Lymphoma Pathology Committee, Southwest Oncology Group, 1988-present.
- Leukemia Pathology Committee, Southwest Oncology Group, 1988-present.
- Leukemia Biology Committee, Southwest Oncology Group, 1990-present.
- Lymphoma Biology Committee, Southwest Oncology Group, 1990-present.
- Named Vice-Chair, SWOG Lymphoma Biology and Pathology Committees, 1994-present.
- Study Coordinator: National SWOG 9800 Phase II Pilot Trial of CHOP Followed by Monoclonal Antibody Anti-CD20 for Treatment of Newly Diagnosed Follicular Non-Hodgkin's Lymphomas. Study opened in May, 1998- active review and research ongoing.
- Study Coordinator: National SWOG 9911 Phase II Pilot Trial of CHOP Followed by Iodine-131-Labeled Monoclonal Anti-CD20 Antibody For Treatment of Newly Diagnosed Follicular Non-Hodgkin's Lymphomas. Study opened in fall of 1999 active review and research ongoing..
- Study Coordinator: National SWOG 0016 Phase III Trial of CHOP vx CHOP+Rituximab vs CHOP+Iodine-131-Labeled Monoclonal Anti-B1 Antibody (Tositumomab) for Treatment of Newly Diagnosed Follicular Non-Hodgkin's Lymphomas. Study opened in April, 2001 - active review and research ongoing.

##### **Association for Molecular Pathology**

- Named Hematopathology Program Committee Chair, AMP, 1995.
- Named to AMP Executive Council, 1996-97.
- AMP Program Chair Elect, 1996.
- AMP Program Chair, 1997.
- Ad-Hoc Journal Affiliation Committee for AMP, 1996-1997.
- Elected Hematopathology Section representative, AMP Clinical Practice Committee, 1998-1999.
- Elected to AMP Executive Council, 2002-2003.
- AMP Program Chair-Elect, 2002.
- AMP Program Chair, 2003.
- AMP Hematopathology Representative to Nominating Committee, 2010-2012

##### **US and Canadian Academy of Pathology**

- Co-Chair - Hematopathology Platform Scientific Session - New Orleans, LA, March, 1993.
- Co-Chair - Hematopathology Platform Scientific Session - March 26, 1996, Washington, D.C.
- Co-Chair – Hematopathology Platform Scientific Session - March 4, 1998, Boston, Mass.
- USCAP Abstract Review Board, Hematopathology Section, 1996.
- USCAP Abstract Review Board, Hematopathology Section, 1997.
- USCAP Abstract Review Board, Hematopathology Section, 1998.
- Invited Co-Chair - Hematopathology Platform Scientific Session – Vancouver, British Columbia, March, 2004.

##### **College of American Pathologists**

- Presenter: CAP Workshop, April 25, 1995, Orlando, Florida. “Molecular Diagnostics in Hematopathology”.
- Presenter: CAP Workshop, September 20, 1995, New Orleans, LA. “Molecular Diagnostics in Hematopathology”.
- Appointed to CAP Molecular Pathology Committee, 2001-2006.

##### **NCI Leukemia/Lymphoma Molecular Profiling Project – NIH Directors Challenge and SPECS Grants**

- NIH-sponsored member of LLMPP Coordinating Committee, May 2002 - 2005

- NIH-sponsored Co-Investigator and Member of LLMPP Pathology Review Board - 2005-2010
- NIH-sponsored Co-Investigator and Member of LLMPP Pathology Review Board - 2001-2016

### Institutional

#### **Oregon Health Sciences University Committee Memberships:**

- Ad Hoc Committee on Unification of Pathology Departments, 1985-86.
- Ad Hoc Committee for Review of Medical Genetics, 1987-88.
- Practice Plan Committee, Department of Pathology, 1989-94, Chairman-1991.
- Faculty Council, 1990-94.
- UMG Board of Directors - appointed 1991-93
- UMG Board of Directors - elected 1993-94.
- Institutional Research Space Committee - 1991-94.
- Oregon Cancer Center, Hematology Program Committee, 1992-present.
- Oregon Faculties Political Action Committee Board of Trustees, 1994.
- Institutional Research Committee - 1992-95, reappointed 1995-98.
- Admissions Interview Subcommittee - 2006-07.
- Admission Committee - 2007-2014.

### Departmental

- Director of OHSU Hematopathology Division, Department of Pathology, 7/84-7/94, 7/98-present.
- Director of OHSU Hematopathology Molecular Diagnostics, 1984-1994.
- Director of Hematopathology Consultation Service, 1984-present.
- Director of Legacy Hospitals Hematopathology Services and the Hoffman Cellular and Molecular Diagnostics Laboratory, 7/94-12/03.
- Consultant for Legacy Hospitals Cascade Pathology group, 1/2003-present.
- Director of OHSU Hematopathology Flow Cytometry, 1984-2001.

## **VI. TEACHING (OHSU Educator's Portfolio):**

### **Overview of your Role as an Educator:**

Although I have done considerable medical student teaching in the past, for the last several years my teaching has been focused on the medical students, pathology residents, and fellows who rotate through the Hematopathology Division. The fellows include both Hematopathology fellows, as well as Adult Hematology-Oncology fellow, Pediatric Hematology-Oncology fellows, and Bone Marrow Transplant fellows. I am the OHSU senior hematopathologist, so I typically spend 5-10 hours per week with housestaff and students, and often with junior faculty as well. I also do several didactic lectures a year for their weekly pathology course. Some previous and current educational activities are listed below:

#### Medical Student:

- Pathophysiology Con 610 - 1st year medical students - 1984-1996.
- Blood/RES Pathophysiology Con 615 - 2nd year medical students - 1985-1996.

#### Resident/Fellow:

- Anatomic Pathology Resident Training - approximately 300 contact hours/year.
- Clinical Pathology Resident Training - approximately 300 contact hours/year.
- Hematopathology Fellow Training – approximately 300 contact hours/year.
- Pediatric Hematology/Oncology Fellow Training – approximately 50 hours/year.
- Adult Hematology/Oncology Fellow Training – approximately 50 hours/year.
- Pathology Resident Teaching Conferences - Malignant Lymphomas and Hematopathology Flow Cytometry and Molecular Diagnostics. (Four hours lecture/year.)

### **Scholarship of Teaching:**

#### Curriculum development

I established a Hematopathology Fellowship Program in 2001, with development of necessary curriculum. I have also developed curriculum for Hematopathology Rotations for residents in Pathology training programs.

#### Educational publications (also listed in section IV)

### Peer-reviewed

1. Bakke AC, Sahin A, and Braziel RM: Applications of flow cytometry in surgical pathology. Laboratory Medicine. 18:590-596, 1986.
2. Mongeon CA, Foucar K, and Braziel RM: Hematopathology ASCP Check Sample - ASCP ChecksampleNo. HP 95-4 (Systemic Polyclonal Immunoblastic Proliferations.) Hematopathology Volume 1, No. 4, 1995.
3. Braziel RM: A multi-institutional perspective: The Southwest Oncology Group Lymphoma Biology Laboratory Experience with Prognostic Markers. Am J Surg Pathol 20: 371-379, 1996.
4. Braziel RM and Oyama K: Mistaken Diagnoses of Hodgkin's Disease. Hematology/ Oncology Clinics of North America. 11:863-892, 1997.
5. Hsi E, Tubbs RR, Lovell MA, Braziel RM, and Gulley ML: Detection of bcl-2/JH translocation by polymerase chain reaction: a summary of the experience of the Molecular Oncology Survey of the College of American Pathologists. Arch Pathol Lab Med 126:902-908, 2002.

### Chapters

1. Cossman J., Neckers, L. M., Braziel, R., Bakhshi, A., Arnold, A., and Korsmeyer, S.: Induction of differentiation in B cell leukemias. In Bernard, A., Boumsell, L., Dausset, J., Milstein, C., and Schlossman, S. F. (Eds.): Leucocyte Typing. Springer-Verlag, 1984.
2. Jaffe ES, Cossman J, Neckers LM, Braziel RM, and Simrell CR: Immunologic phenotype of non-Hodgkin's lymphomas: Correlation with morphology and function. In: Cavalli, F. (Ed.) Malignant Lymphomas and Hodgkin's Disease: Experimental and Therapeutic Advances. Martinus Nijhoff, Boston, pp. 25-36, 1985.
3. Braziel RM, Hsu SM, and Jaffe ES: Lymph nodes, spleen, and thymus. In Spicer, S. S. (Ed): Histochemistry In Pathologic Diagnosis. Marcel Dekker, Inc., New York/Basel, 1986.
4. Braziel RM and Sacker A: Gene rearrangements in malignant lymphomas. In: Dana, B. (Ed.) Malignant Lymphomas. Kluwer Academic Publishers, pp. 147-165, 1993.
5. Perkins ML, Odell JM, and Braziel RM: Introduction to leukemia and the acute leukemias. In: Harmening, D.M. (Ed.) Clinical Hematology and Fundamentals of Hemostasis. F.A. Davis Company, Publishers, 1995.
6. Braziel RM and Fan G: Molecular diagnosis of B-cell lymphoma. In: Leonard, DGB (Ed.) Molecular Pathology in Clinical Practice. Springer Sciences+Business Media, LLC, pp. 349-364, 2007.
7. Cruz F, Gatter K, and Braziel RM: Introduction to leukemia and the acute leukemias. In: Harmening, DM. (Ed.) Clinical Hematology and Fundamentals of Hemostasis. 2008.
8. Braziel R, Fan G, Leeborg N, and Dunlap J: Molecular diagnosis of B-cell malignancies. In: Schriver, I (Ed) Molecular Pathology in Clinical Practice. Springer Sciences+Business Media, LLC, 2012.

### Educational conference presentations (also listed in section IV):

1. Lecture: Oregon Society for Histotechnology, 1985, Portland, OR. "Technical Aspects of the Diagnosis of Malignant Lymphomas".
2. Lecture: Portland-Area Laboratory Consortium for Education, April 1986, Portland, OR. "Clinical Utility of Cell Surface Markers".
3. Lecture: Oregon State University Histochemistry Symposium, 1986, Corvallis, OR. "Clinical Applications of Immunoperoxidase Technique in Humans".
4. Lecture: Northwest Medical Laboratories Symposium, 1987, Portland, OR. "Hematologic Disease in the Elderly".
5. Lecture: St. Charles Medical Center CME Program, March 1988, Bend, OR. "Diagnosis of Lymphoproliferative Disorders".
6. Lecture: Pacific NW Pathology Assoc. Symposium, May 1989, Semi-Ah-Moo, WA. "Diagnosis of Acute Mixed Lineage Leukemias".
7. Lecture: Oregon Dermatology Society Lecture, October 1991, Portland, OR. "Immunophenotyping and

- Genotyping of Skin Lymphoid Infiltrates”.
8. Lecture: Oregon Pathologists Association Lecture, February 1991, Portland, OR. "Lymphoproliferative Disorders”.
  9. Lecture: National Meeting of American Association of Pathology Assistants, 1992, Seattle, WA. "Immunophenotypic and Genotypic Analysis of Malignant Lymphomas”.
  10. Lecture: College of American Pathologists Workshop, April 25, 1995, Orlando, Florida. “Molecular Diagnostics in Hematopathology”.
  11. Lecture: Pacific NW Pathology Association Symposium, May 19-20, 1995, Salishan Lodge, Gleneden Beach, OR. “Gastrointestinal Lymphomas”.
  12. Lecture: College of American Pathologists Workshop, September 20, 1995, New Orleans, LA. “Molecular Diagnostics in Hematopathology”.
  13. Lecture: Association for Molecular Pathology annual meeting, November 10-12, 1995, Minneapolis, MN. Hematopathology workshop speaker, “Update on Molecular Diagnostics in Leukemias and Lymphomas”.
  14. Lecture: Oncology Grand Rounds, Meridian Park Hospital, January 10, 1996. “The Use of Adjunctive Studies in the Diagnosis of Malignant Lymphomas”.
  15. Lecture: US and Canadian Academy of Pathology - Society for Hematopathology Companion Meeting, March 24, 1996, Washington, D.C. “A Multi-Institutional Perspective: The Southwest Oncology Group (SWOG) Lymphoma Biology Laboratory Experience with Prognostic Markers”.
  16. Moderator for Workshop on Acute Leukemias - Association for Molecular Pathology, November 13-15, 1996, Baltimore, Maryland.
  17. Lecture: Oregon Pathologists Association, September 21, 1996. “Molecular Diagnostics in Hematopathology”.
  18. Lecture: Good Samaritan Hospital Cancer Conference, Portland, OR, September 24, 1997. “Advances in Lymphoma Classification: Impact on Diagnosis, Prognosis, and Treatment”.
  19. Lecture: Good Samaritan Hospital Cancer Conference, Portland, OR, September 9th, 1998. “Prognostic Markers in Non-Hodgkin’s Lymphomas”.
  20. Lecture: Portland-Area Laboratory Consortium for Education, September 11, 1999, Portland, OR. "Update on Lymphoid Malignancies - Phenotypes and Genotypes”.
  21. Lecture: Association for Molecular Pathology annual meeting – Hematopathology Workshop, November 7, 1999, St. Louis, MO. “Hematopathology Molecular Diagnostics Sample Exchange Program”.
  22. Lecture: Portland-Area Laboratory Consortium for Education, September 9, 2000, Portland, OR. “The Role of Special Studies in Diagnosis of Leukemias and Lymphomas: An Update.”
  23. Lecture: Oregon Pathologists Association Seminar, October 7, 2000, Portland, OR. "Bone Marrow Pathology 2000: Update on Diagnosis of Hematologic Malignancies.”
  24. Lecture: Oregon Spring Seminar, May 5, 2001, Eugene, OR. “Update on Hematologic Malignancies; Diagnosis of Malignant Lymphomas”.
  25. Lecture: speaker and chair – American Society of Hematology Education Session, December 6, 2003, San Diego, CA. “Molecular Diagnostics of Hematologic Malignancies”.
  26. Lecture: 2004 Spring Seminar – Washington State Society for Clinical Laboratory Science and Northwest State Society of American Medical Technologists – April 30, 2004, Vancouver, WA. "An Update on the Role of Adjunctive Laboratory Studies in the Diagnosis and Follow-Up of Patients with Hematologic Malignancies”.
  27. Lecture: Canadian Academy of Pathology – July 2004, Montreal, Canada. "Molecular Diagnosis of Hematologic Malignancies”.
  28. Lecture: Association for Molecular Pathology Annual Meeting – November 13, 2004, Los Angeles, CA. "Is It Time to Adopt Molecular Classifications for the Primary Diagnosis of Lymphoma?”.
  29. Lecture: Training Practicum for BMS – February 2, 2011, Portland, OR. “CML Pathology: Blood and Bone Marrow Findings”.
  30. Lecture: Novartis CML Educational Practicum – March 22, 2012, Portland, OR. “Pathology in Ph (+) Leukemias”.
  31. Invited FDA Expert Panel Member: “Minimal Residual Disease Workshop”, sponsored by ASCO, AACR, and ASH. Bethesda, MD, 4/18/2012.
  32. Lecture: Association for Molecular Pathology Annual Meeting – October 25, 2012, Long Beach, CA.. "Guidelines for Interpretation of Lymphoid Clonality Testing”. Workshop presentation with Drs. Patricia Groenen and James Cook.
  33. Lecture: Novartis CML Educational Practicum – June 4, 2013, Portland, OR. “Pathology in Ph (+) Leukemias”.
  34. Lecture: Challenges in Diagnosis and Treatment of Aggressive B-cell Lymphomas – Oregon Pathologists Association Seminar, March 15, 2014, Portland, OR.

